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Bacterial infections are the main cause of chronic infections and even mortality. In fact, due to 
extensive use of antibiotics and, then, emergence of antibiotic resistance, treatment of such 
infections by conventional antibiotics has become a major concern worldwide. One of the 
promising strategies to treat infection diseases is the use of nanomaterials. Among them, 
mesoporous silica materials (MSMs) have attracted burgeoning attention due to high surface 
area, tunable pore/particle size, and easy surface functionalization. This review discusses how 
one can exploit capacities of the MSMs to design and fabricate multifunctional/controllable 




of bacterial and biofilm resistance towards conventional antimicrobials and then discusses 
how nanoparticles exert their toxic effects upon pathogenic cells. Next, it introduces the main 
aspects of MSMs (e.g. physico-chemical properties, multifunctionality and biosafety) which 
one should consider in the design of MSM-based DDSs against bacterial infections. Finally, a 
comprehensive analysis of all the papers published dealing with the use of MSMs for delivery 
of antibacterial chemicals (antimicrobial agents functionalized/adsorbed on mesoporous silica 
(MS), MS-loaded with antimicrobial agents, gated MS-loaded with antimicrobial agents, MS 
with metal-based nanoparticles and MS- loaded with metal ions) is provided. 
 
1. Introduction 
Antimicrobials are compounds able to locally kill bacterial cells (i.e., bactericidal agents), 
inhibit or slow down their growth (bacteriostatic compounds).
[1] 
Among the various 
substances acting as antimicrobial agents, we find pure natural products (e.g., 
aminoglycosides), chemically modified natural substances, which include most of the 
antibiotics used today (e.g., beta-lactams and cephalosporins),
[2] 
or completely synthetic 
compounds.
[3]
 Although the antimicrobials available up to date are chemically diverse, 
pathogenic microorganisms are able to develop resistance mechanisms against them, leading 
to their loss of efficacy when used in clinical settings.
[4]
 The emergence of bacterial resistance 
to antimicrobials has mainly arisen from their extensive misuse in both agriculture and human 
health services,
[5]
 leading to: (i) inheritable evolutionary processes or (ii) horizontal gene 
transfer phenomena between different pathogenic microorganisms.
[1],[6]
 To date, the number 
of reports on the antimicrobial resistance (AMR) of pathogen microorganisms is 
exponentially growing, as highlighted by the World Organization for Animal Health, the Food 
and Agriculture Organization, and the World Health Organization, which indicated AMR as a 
serious threat towards human and animal health, and, subsequently, an economic and social 
concern as well.
[7,8]




towards the conventional antimicrobials led to the generation of the so-called “superbugs” 
that are not affected by the antibacterial treatments available these days, causing the spread of 
infections that increase the severity of illness and subsequent human death rates.
[9]
  
A crucial factor contributing to the spread of AMR among microorganisms is their ability and 
preference to create, in most of the natural settings, multicellular aggregates that live closely 
associated to interfaces or surfaces.
[10–12]
 Although such microbial systems were already 
observed in 1600’s,
[13]
, was not until 1978 these complex communities were defined as 
biofilms, and they are now recognized as the primary form of bacterial life compared to the 
“free-swimming” planktonic cells.
[10,11]
 Biofilms are generated through a staged process in 
which both planktonic cells and those adhering to a surface are present.
[13,14]
 Upon attachment, 
bacterial cells start to produce the so-called Extracellular Polymeric Substance (EPS) or 
matrix, which is also indicated as the ‘slime’ layer on a surface, and contains a high amount of 
water, polysaccharides, proteins, extracellular-DNA (e-DNA) and lipids.
[13,14]
 The presence of 
EPS ensures the protection of bacterial cells from several external stresses, such as 
desiccation, oxidation, UV radiation 
[15]
. Moreover, the thickness and the chemistry of the 
EPS matrix constitutes a barrier for biocides, antibiotics and metallic ions, limiting their 




During the life cycle of bacterial biofilms, several intra- and inter -cellular signaling processes 
occurs (e.g., quorum sensing), which can result in enhancing of AMR in these communities. 
[16]
 Additionally, the presence within biofilms of bacterial cells in different physiological 
states can lead to the development of AMR phenomena.
[13]
 Indeed, the diverse physiology of 
the so-called “persister cells”, which are dormant and non-dividing cells,
[17,18]
 confers them 
the ability to survive the presence of several antimicrobials, as they are not effective against 
metabolically inactive cells as targets.
[19]
 A similar dormant and non-growing state has been 




phase variants, as internal signalling by cyclic-di-GMP gives them a different phenotype 
compared to the parental ones.
[20–22]
  Thus, their different phenotype results in their less 
susceptibility towards antibiotics, leading to the ability of these phenotypic variants to survive 
even at high concentrations of antibiotics.
[23,24]
  
Considering the structural and physiological complexity of biofilms, those formed by 
pathogen bacteria are able to populate settings in which sterility is of fundamental importance 
for human health (e.g., food processing facilities, dental hygiene equipment, catheters, 
orthopedic implants).
[13],[25]
 As a result, microorganisms living as complex communities are 
responsible for 85% of human bacterial infections in the Western world.
[26]
 Although high 
resistance towards antibiotics is typical of pathogenic biofilms and is well documented, 
pathogenic infections in the form of biofilms are still treated with these antimicrobial 
compounds 
[4]
. Moreover, since antibiotics are typically from 100 to 1000 times less efficient 
in the case of biofilms,
[27]
 to obtain significant antimicrobial effect against these infections, it 
is necessary to administer higher antibiotic dosage than those established for planktonic cells. 
However, host organisms are often not capable of tolerating these high levels of 
antimicrobials, leading to either (i) detrimental side effects or (ii) the use of lower dosage, 
resulting in inefficient treatment.
[4]
 In this scenario, the development of new and alternative 
antimicrobial compounds with long-term efficiency in preventing the reoccurrence of both 
planktonic and biofilm infections is recognized as an immediate and fundamental need in 
agriculture, livestock, as well as in the human biomedical field.  
 
1.1. Nanoparticles as new effective antimicrobial agents  
The exponential development of nanotechnology we have witnessed in the last 30 years has 
guaranteed the possibility to tune chemical-physical features of antimicrobial compounds at 






nanomaterials are considered to date novel therapeutic agents and the most promising 
alternative to the conventional antimicrobials.
[29]
  
Nanomaterials exhibit unique features as compared to their bulk counterpart, mostly reliant on 




. Indeed, when synthetic compounds are scaled down to 
approach the atomic level, new mechanical, chemical, electrical, optical and magnetic 
properties arise, making them suitably manipulated for different applications.
[30]
 Particularly, 
nanostructures are featured by a high surface-to-volume ratio,
[1]
 which determines a surface 
area much larger as compared to their size, enhancing the contact of these nanomaterials with 
the microorganisms.
[29]
 Thus, the increased possibility of interaction between nanosized 
formulations and pathogenic cells leads to the activation of a broad range of antimicrobial 
mechanisms,
[29]
 therefore improving the antimicrobial efficacy of these nanomaterials. Further, 
the antimicrobial activity of nanostructures can be influenced by other chemical-physical 
parameters, such as shape, chemical modification or coating, and the generation of mixed 
population of different nanocomposites.
[31]
  
Although a great variety of nanomaterials with different morphology have been developed, 
nanoparticles (NPs) are those most investigated for medical and antimicrobial purposes, 
mainly as a consequence of their regular structure, which better allows a prediction of their 
interaction with both eukaryotic and prokaryotic cells. In this context, NPs have found 
important applications in biomedicine (e.g., drug delivery, imaging, sensing, coating for 
artificial implants),
[32]
 as they shared the size range with biological molecules involved in the 
major processes occurring within the cells.
[29]
  
A general and broad classification of NPs is based on their composition, allowing to 
distinguish between organic and inorganic nanomaterials.
[29]
 Indeed, organic NPs contain 
antimicrobial polymers (quaternary ammonium compounds,
[33]


















cells, exerting an enhanced antimicrobial effect.
[4]
 Nevertheless, since a common feature of 
organic NPs is their poor stability in various conditions (temperature ranges, pH and ionic 
conditions, solubility), their design for antimicrobial purposes tends to be more challenging.
[4]
 
Therefore, inorganic formulations are now considered the preferential choice as new NP 
antimicrobials. Particularly, NPs made of metals, metal oxides and metalloids have received 
increasing interest as metals have intrinsic antimicrobial properties.
[29],[39]
 Indeed, metal 
compounds containing silver or copper have been used since ancient times to treat burns or 
chronic wounds, and to make water potable.
[29],[40]









 copper oxide (CuO)
[44]
 and zinc oxide 
(ZnO) NPs,
[45]
 and mesoporous silica (MS) have been greatly investigated for their 
antimicrobial efficacy.   
 
2. Mesoporous silica nanostructures 
Since their inception in the early 1990,
[46,47]
 mesoporous silica (MS) structures (e.g.,SBA-, 
MCM-, KIT, HMS, FDU and MSU-family) have attracted a lot of attention in fundamental 




), tunable pore size (2-5 nm) 
and particle dimensions (typically <200 nm), controllable morphology (e.g., rod, spherical, 
platelet, and ellipsoid), high mechanical/thermal stability, easy large-scale preparation (even 
at kilogram scale) and their selective functionalization on both interior and exterior 
surfaces.
[48–52]
 Besides the appealing properties, high biocompatibility and good 
biodegradability of the porous structures allow one to design and fabricate powerful delivery 
systems for different applications.
[49,50],[53,54]
 Synthesis of MS is rather feasible and it is based 
on sol-gel chemistry, which involves two main steps: hydrolysis and condensation of silica 
(organo silica) precursors around a template generated via supramolecular self-assembly of 
surfactants in aqueous solution, followed by the elimination of the template by using 
calcination or solvent extraction.
[47],[55]




biological systems and their biological behavior (e.g., cytotoxicity, biocompatibility, 
biodegradability and tissue compatibility) depend heavily on physico-chemical properties 
(PCPs) of the NPs (e.g., shape, pore/particle size and surface properties).
[53],[56,57]
 Therefore, 
the tuning of the PCPs acquires significant thought to achieve an appropriate biological 
performance (Figure 1).  
Traditional synthesis employing small molecule surfactants such as cetyl trimethylammonium 
bromide (CTAB) as structure directing agent (SDA) produced MS with pore diameter less 
than ~ 5 nm, limiting their application in accommodating large guest (cargo) molecules. Such 
concerns has led to the development of synthesis through pore-extended MS for drug delivery 
systems. In general, the pore sizes of MS can be tuned through the use of tetra-
alkylammonium salts featured by different alkyl chain lengths and pluronic (or non-pluronic) 
surfactants with diverse molecular weights. Along with pore and particle size, particle shape 




The high surface area and the high amounts of  silanol groups on MS surface make  possible 
to prepare hybrid organic-inorganic nanomaterials through surface functionalization, allowing 
to better control their loading capacity, cargo release rate, cellular uptake efficiency, etc.
[57]
 
The functionalization of MS generally occurs through three pathways: 1) grafting method, 2) 
co-condensation method, and 3) direct incorporation of organic units into the silica wall to 
obtain periodic mesoporous organosilicas (PMOs) or mesoporous organosilica nanoparticles 
(MONs) (Figure 1).    
As mentioned in the above sections, internal/external surface of MS can be functionalized by 
diverse agents (Sheme 1), resulting in great opportunities to design and construct antibacterial 
structures for instance due to the attachment of well-known bactericides, by including the 
bactericides in the pores for a sustained cargo release or via the incorporation in the MS 




are feasible structures to generate effective DDSs, it is imperative to control the pore opening, 
which in turn is responsible for the cargo releasing.
[58,59]
 Thus, once the mesopores are loaded 
with a cargo, the pore outlets of the MS can be blocked by diverse organic or inorganic 
“molecular gates” to prevent undesired premature leakage. Moreover, the pore-blockers 
should respond to appropriate external or internal triggers to close or open the well-defined 












 poly(acrylic acid) (PAA) brush
[67]
), 






















 and reduced graphene
[78]







 and proteins 
[89–92]
) have been employed under certain 















 and or a 
combination of these stimuli
[67],[76]




An important feature of multifunctional MS to consider for the design delivery systems is 
their possibility to selectively deliver antimicrobians to prevent unwanted side effects to 
healthy cells caused by non-targeted release. In order to achieve this goal, passive or active 
targeting, or combination of them is required.
[49,59,62,114]
 In cancer therapy, passive targeting 
relies on the enhanced permeability and retention (EPR) effect of tumors, an effect of their 
unique physiology and metabolic rates.  Existing evidences showed that EPR effect not only 
present in tumors, but also exist in bacterial infections.
[115,116]
 Indeed, it has been shown that 
diffusion of therapeutic-NPs into biofilm was highly depended on PCPs of  NPs (e.g.,  
size
[117,118]
 and surface charge
[119–121]
), demonstrating EPR effect in biofilm drug delivery. 




been systematically investigated. Moreover, in order to overcome the associated limitations of 
passive targeting approach, active targeting as an effective/complementary way can be 
considered. This is usually achieved by decorating external surface of the NPs with targeting 
ligands. In drug delivery to bacteria/biofilms, however, targeted-MSNs have been scarcely 
used as drug carrier.
[87,88,122,123]
 As an example the disaccharide trehalose has been used as 
targeting ligand TL for targeted drug delivery to mycobacteria (vide infra). Moreover, one of 
the biggest challenges when using antimicrobials is AMR. Due to high surface area, tunable 
surface charge/pore size of MS and the possibility of creating hierarchical structures and gated 
supports, the mesoporous structures can be considered as an excellent candidates for 
codelivery antimicrobials to circumvent AMR. In general, AMR can occur through different 
processes in microorganisms, such as increasing bacterial efflux pumps, decreasing the drug 
uptake, expression of specific gene inactivating antibiotic drugs, alteration of drug targeting 
sites, reducing antibiotic effectiveness, and biofilm formation.
[124]
 One of the efficient ways to 
combat AMR is packaging of multiple antibacterial drugs within the same NP. This all-in-one 
systems can overcome AMR mechanisms, because it is unlikely possible that bacterial cells 
can develop multiple simultaneous resistance mechanisms to counteract the multiple 
simultaneous gene mutations induced by the integrated systems. However, there are relatively 
few examples of codelivery of by MSN-based carriers to overcome AMR. 
Moreover, MSNs hold great potential in order to integrate therapeutic and diagnostic 
functions (such as imaging contrasting agents) within a single system to create unique 
structures.
[125,126]
 In this context, various nanocomposites (e.g. MSN-magnetic NPs,
[126]
 MSN-




 and MSN- upconversion 
NPS
[129,130]
) designed/fabricated for different applications that can be also used in the 
treatment of bacterial infection. It should be emphasized that the core of the MS can serve not 
only as imaging tool but also acts as therapeutic function. For example the magnetic, gold, 






 Beside the therapeutic capability of core, the mesoporous silica 
shell can act as excellent reservoirs to load/controlled release drugs, thus demonstrating 
application of the sandwich-structured nanomaterials as promising platform for synergistic 
therapy.  
For any nanoparticle, which will be employed as therapeutic carrier/agent, it is essential to 
assess its interaction with the body (cells, tissues and organs) to avoid adverse effects. 
Encouragingly, many studies have been showing that MSNs are non-toxic and biocompatible 
if they are prepared with appropriate structural/compositional features and used with 
appropriate dosages. However, given that size, shape, pore diameter, surface properties, 
composition, and concentration features can all contribute to this aspect of MS NPs, it is hard 
to state generalities regarding the biocompatibility of the silica-based carriers to describe their 
adsorption, distribution, metabolism and excretion (ADME) properties.
[53,57]
 In order to 
achieve acceptable therapeutic results and mitigate side effects of MS NPs in nanomedicine 
applications, biodistribution of MS NPs to healthy tissues should be reduced as much as 
possible while targeting in infecting bacterial cells. Similar to other ADME properties, 
biodistribution of MS NPs is highly depend on their PCPs.
[53,56]
 
Silica-based NPs is hydrolytically unstable and is gradually converted to silicic acid or 
polysilicic acid which are nontoxic and can safely be excreted/absorbed by the human 
body.
[131,132] 
Moreover, today it is possible to design highly biodegradable MS NPs.
[132] 














) inside the silica framework could control degradation kinetics of MS NPs. 
Surface modification can also alter degradation rate of MS NPs.
[138,139]
 For instance, there are 
examples showing that PEGylation can reduce degradation kinetic MS NPs,
[140,141]
 whereas 
extended pore size MS exhibited faster degradation.
[142] 
Apart from the mentioned PCPs, 










This review intends to be a comprehensive analysis of all reports published until the first 
months of 2019 using MS for antibacterial applications. Chart 1 shows the chemical 
structures of the cargos loaded into the MS supports used in the preparation of antibacterial 
materials. Table 1 contain a summary of MS-based antibiotics against diverse 
microorganisms. The review is arranged around the different use of the antimicrobials and the 
form they are used in combination with MS and is divided in five sections: (i) antimicrobial 
agents functionalized/adsorbed on MS, (ii) MS loaded with antimicrobial agents, (iii) gated 
MS loaded with antimicrobial agents, (iv) MS with metal-based NPs and (v) MS loaded with 
metal ions. This review concludes with a section that discusses future perspectives. 
 
3. MS in antibacterial applications 
 
3.1. Antimicrobial agents functionalized/adsorbed on MS 
This section describe MS that are functionalized with antimicrobial molecules or MS 
containing adsorbed antimicrobial molecules in which the bactericidal effect is not due to the 
delivery of the cargo but to the interaction of the functionalized/adsorbed molecules with 
bacteria or the generation of toxic species for instance by adsorbed/functionalized molecules 
with antibacterial photodynamic activity. Reported examples are based in the use of MCM-41 
type mesoporous silica nanoparticles, although also some examples using SBA have been 
reported. In most cases the antibacterial efficacy of the prepared materials are significantly 
higher than that of free antimicrobials due to an effective raising of the local concentration of 
the antimicrobial due to its anchoring or adsorption on the MS. 
Several examples are based in the functionalization of MS with small molecules such as 




prepared by Wang et al. and used for the recognition of gram + bacteria in the presence of 
macrophages and also for the inhibition of bacterial growth.
[146]
 For this purpose, the 
nanoparticles were functionalized with aminopropyl moieties and vancomycin was covalently 
grafted through an amidation reaction using EDC/NHS. Moreover, the solid was covalently 
functionalized with fluorescein isothicyanate. Confocal laser scanning microscopy studies 
showed that prepared nanoparticles were able to selectively recognize gram + bacteria (S. 
aureus) in the presence of gram – counterparts (E. coli). This selective recognition was 
ascribed to the fact that vancomycin, grafted on the outer surface of the NPs, form a five-point 
hydrogen bonding interaction with the terminal D-Ala-D-Ala moieties of the -1,4-linked-N-
acetylglucosamine and N-acetylmuramic acid peptide on the S. aureus membrane. On the 
other hand, the prepared nanoparticles presented a marked inhibition of S. aureus growth with 
a minimum inhibitory concentration of 200 g mL
-1
. Scanning electron microscopy studies 
showed that cell walls of S. aureus started to collapse after 12 h of nanoparticles 
administration, which led to cell death. Finally, the antibacterial activity of the NPs was also 
tested in vivo in a mice model with remarkable results; a remarkable decrease of bacteria in S. 
aureus infected tissues. 
The essential oil components carvacrol, eugenol, thymol and vanillin were covalently 
anchored onto three different MS supports (fumed silica, amorphous silica and MCM-41) and 
the antibacterial properties of the prepared materials tested against E. coli and L. Innocua.
[147]
 
For the covalent immobilization of carvacrol, eugenol and thymol onto the inorganic siliceous 
supports, the aromatic compounds were functionalized with aldehyde groups using well-
known formylation protocols. Then, in a second step, the aldehyde-containing derivatives 
were reacted with (3-aminopropyl)triethoxysilane. In the case of vanillin, direct reaction with 
(3-aminopropyl)triethoxysilane yielded the final silane compound. The four silane derivatives 
were directly grafted onto the MS supports. The prepared materials presented enhanced 




components. The antimicrobial activity was influenced by both the grafted essential oil 
component and by the inorganic support. Besides, nanoparticles functionalized with thymol 
and vanillin were used to eliminate L. innocua incorporated into pasteurized milk 
demonstrating their effectiveness in reducing bacterial content in a real food system.  
Delgado and co-workers prepared MCM-41 MS NPs functionalized with lysine and studied 
the adhesion of S. aureus and E. coli onto the functionalized scaffold.
[148]
 In afirst step the 
authors functionalized the surface of the MS NPs with cyanuric chloride, which was then 
reacted with a lysine-Cu(II)-lysine complex. This reaction yielded the final system grafted 
with lysine amino acid in its zwitterionic form. Confocal microscopy studies showed that E. 
coli and S. aureus were unable to form biofilms onto the lysine-modified nanoparticles as the 
zwitterionic moieties onto the surface of the nanoparticles decreased the attachment of both 
bacteria. 
Several examples of SBA-15 functionalized in the surface with different groups showing 
antibacterial activity were reported by Pędziwiatr-Werbicka et al that used silylated natural 
fatty acids (1-6, derivatives of undecenoic and oleic acids, see Figure 2) to functionalize the 
external surface of SBA-15 particles by grafting and for the synthesis of PMOs.
[149] 
The 
different prepared materials presented several degrees of bacterial inhibition growth (in the 
10-50% range) depending on the functionalization and the bacteria (S. aureus, E. coli, S. 
epidermis, P. vulgaris and P. aeruginosa). The most active solids was a SBA-15 support 
functionalized with the fatty acid derivative 3 and a PMO synthesized using 6. Addition of 
both materials to the selected gram – bacteria induced moderate reduction growths in the 20-
40% range. 
El Kadib and co-workers prepared SBA-15 simply functionalized with amino, thiol and 
carboxylic acid moieties and tested their antibacterial properties.
[150]
 Bare SBA-15 was unable 




best results were obtained with SBA-15 functionalized with amino and thiol groups, yet were 
only able to reduce the growth of S. epidermis by 18-20%. 
Lysozyme-adsorbed MS NPs as efficient in vitro and in vivo antibacterial agent was 
developed by Li and Wang.
[151]
 The material showed high antibacterial effect over 24 h 
against E. coli. The lysozyme corona provided multivalent interaction between the support 
and bacterial walls and consequently raised the local concentration of lysozyme, which 
promoted hydrolysis of peptidoglycans and increased membrane perturbation. The minimal 
inhibition concentration (MIC) of the lysozyme-adsorbed MS (75 g mL
-1
) was fivefold 
lower than that of free lysozyme in vitro (400 g mL
-1
). Furthermore, the antimicrobial 
efficacy was also evaluated in vivo by using an intestine-infected mouse model. Experimental 
results indicated that the number of bacteria surviving in the colon was three orders of 
magnitude lower than in the untreated group. Moreover, the support demonstrated low 
cytotoxicity and negligible hemolytic side effects. 
Several examples reported the use of MS coated with N-halanine-based polymers. In fact, 
antimicrobial N-halamine polymers have been extensively studied in the last decade thanks to 
their effectiveness toward a broad spectrum of microorganism.
[152]
 Zou and co-workers 
prepared MS NPs coated with poly(1-allylhydantoin-co-methyl methacrylate) using radical 
polymerization. Subsequent chlorination with hypochlorous acid yielded the final N-halamine 
decorated NPs.
[153]
 Time killing assays carried out with the prepared nanoparticles indicated 
that were able to inactivate bacterial growth in a remarkable fashion; 95 and 98% of reduction 
for E. coli and S. aureus after 10 min, respectively. 
In a similar line Ren and co-workers covalently anchored the poly (5,5-dimethyl-3-(3’-
triethoxysilylpropyl)-hydantoin) polymer to SBA-15 microparticles and in a second step 
chlorinated the polymer with sodium hypochlorite to generate N-halamine groups.
[154]
 The 
final material showed excellent antibacterial activity against S. aureus and E. coli, inactivating 
both bacterial strains in 1 min. The same authors also prepared SBA-
15




with another N-halamine polymer.
[155]
 In this case the external surface of the mesoporous 
support was functionalized with 3-(trimethoxysilyl)propyl methacrylate and then polymerized 
with acryloyl ester of 3-(3’-hydroxypropyl)-5,5-dimethylhydantoin. Finally, clorination with 
sodium hypochlorite yielded the final N-halamine-functionalized material. The prepared 
microparticles were able to inactivate S. aureus and E. coli in ca. 5 min by the direct transfer 
of oxidative chlorine atoms to the microbial cell walls, which induced the rupture of receptors 
in cells and inhibited enzymatic and metabolic processes. The same authors also used the 
mesoporous materials on the modification of cotton.
[156]
 Soaking in household bleach, the 
coated cotton showed good antimicrobial efficacy against S. aureus and E. coli. The 
chlorinated samples were completely inactivate 100% S. aureus within 10 min, and 99.99% E. 
coli within30 min.  
Some other reported examples are based in mesoporous particles coated with other polymers 
containing antimicrobial carbazole or imidazole heterocycles. Sharma and co-workers 
prepared several vinyl carbazole–SBA-15 nanocomposites for antibacterial activity 
studies.
[157] 
Carbazole derivatives have been reported to show antibacterial and anti-yeast 
activities.
[158]
 In this case, the authors loaded SBA-15 mesoporous silica with different 
quantities of styrene and vinyl carbazole monomers and with fixed amounts of divinyl 
benzene (cross-linker) and ,’-azoisobutyronitrile (radical initiator). Using this method, 
several SBA-15 particles with a carbazole-containing co-polymer were prepared. The 
antibacterial behavior of the prepared systems was tested against S. aureus, S. mutans, E. coli 
and S. typhi. All nanocomposites were able to inhibit bacterial growth being the lower MIC 
(350, 200, 320 and 640 g mL
-1 
for S. aureus, S. mutans, E. coli and S. typhi respectively) for 
the material containing the higher amount of the vinyl carbazole monomer. The antimicrobial 
activity of the particles was attributed to the disruption of bacteria membrane probably 




The same authors used a similar strategy to prepare vinyl imidazole–SBA-15 NPs and tested 
their antibacterial activity against S. aureus, S. mutans, E. coli and S. Typhi.
[159]
 This is in line 
with the extensive work done on heterocycles, especially the imidazole ring, to obtain 
derivatives with potential antibacterial properties.
[160]
 The final nanocomposites were 
prepared using an identical procedure to that described above but using a vinyl imidazole 
monomer instead of vinyl carbazole. Again, all the nanocomposites prepared showed 
antibacterial activity being the most active that with the higher vinyl imidazole content (MIC 
in the 320-500 g mL
-1 
range). The antibacterial activity of the nanocomposites was ascribed 
to electrostatic (between the positively charged imidazole and the negatively charged bacterial 
membranes) and hydrophobic interactions (between the alkyl chain of vinyl imidazole and the 
cytoplasmic membrane of bacteria) that induced an agglomeration of the NPs on bacterial 
membranes resulting in its disruption. 
Another approach in this section is the functionalization or adsorption onto mesoporous silica 
supports of molecules and nanoparticles able to display antibacterial photodynamic activity. 
Examples using Rose Bengal, protoporphyrin IX, etc have been reported. Polarz
 
and co-
workers developed sunlight-triggered PMOs functionalized with thiols.
[161]
 In one type of the 
materials, Rose Bengal (RB), as an efficient reactive oxygen species (ROS) producer, was 
covalently bound to the thiol-PMO. In the second type of materials, nitric oxide (NO·) was 
functionalized on the thiol-PM, transforming the thiol groups into S-nitrosothiol 
functionalities. Besides, the oxidation power of RB-thiol-PMO alone and in combination with 
NO-thiol-PMO using sunlight as a trigger was evaluated. The simultaneous release from NO-
thiol-PMO of nitric oxide (NO·) in combination with ROS leaded to the emergence of the 
highly reactive peroxynitrite molecules (ONOO
-
) with significantly enhanced biocidal activity. 
The high antibacterial efficiency of dual action nanoparticles was demonstrated using 




Antibacterial photodynamic activity of the photosensitizer methylene blue-loaded amino-
functionalized (AM-MS) or mannose-functionalized (M-MS) MS NPs were developed by 
Nonell and co-workers (Figure 3).
[162]
 Antimicrobial assays were developed against E. coli 
and P. aeruginosa. The studies showed that methylene blue adsorbed on the NPs was capable 
of efficiently inactivating E. coli and P. aeruginosa upon exposure to red light. The 
antibacterial photodynamic activity was similar to that of free methylene blue but, in the case 
of E. coli, the NPs clearly reduced the dark toxicity of methylene blue while preserving its 
photoinactivation activity. In the case of P. aeruginosa, M-MS showed higher antibacterial 
activity than observed when using AM-MS.  
Nonell, Latterini and co-workers prepared different silica-protoporphyrin IX (PpIX) 
derivatives as antimicrobial agents.
[163]
 The systems - compact silica nanoparticles (CSNP), 
mesoporous silica nanoparticles (MPSAm), stellate mesoporous silica nanoparticles (MPSSt) 
and larger pore mesoporous silica nanoparticles (MPSLP) – functionalized with PpIX were 
synthesized to evaluate the morphology-dependence of the nanomaterials in the singlet 
oxygen production and their bacterial efficiency against S. aureus. The studies showed that 
singlet oxygen production was higher in the sample with the greatest pore volume (i.e PpIX-
MPSLP). Moreover, photoinduced antimicrobial tests of PpIX-doped silica nanoparticles for 
15 minutes, confirmed the antimicrobial effect of the PpIX-CSNP, PpIX-MPSSt and PpIX-
MPSLP. However, PpIX-MPSAm did not develop any photo-induced antibacterial activities.  
 
3.2. MS loaded with antimicrobial agents 
In this section, examples of MS able to deliver an antimicrobial molecule are described. Most 
reported examples use classical MS derivatives loaded with well-known small molecules 
acting as antimicrobials such as caprylic acid, tetracycline, isoniazid, amoxicillin, and 




applications have also been reported (vide infra). Moreover, MS loaded with antimicrobials 
but also containing AgNPs are described in section “MS with metal-based NPs”.  
For instance, MCM-41 type MS NPs loaded with caprylic acid were prepared by Marcos et al., 
and their antibacterial activity against E. coli, S. enterica, S. aureus and L. monocytogenes 
was studied.
[164]
 The prepared nanoparticles showed a total inhibition of bacterial growth at 
concentration of released caprylic acid in the 18.5-20 mM range. Transmission electron 
microscopy images revealed that the released caprylic acid disrupted the bacterial membrane 
with subsequent leakage of cytoplasmic content and cell death. 
Di Pasqua and co-workers prepared two different sized tetracycline-containing MS particles 
(41 ± 4 nm and 406 ± 55 nm) for the treatment of E. Coli.
[165]
 A burst release was observed in 
both formulations and the drug was released by after 5 h, although most tetracycline was 
released over the first hour. Antimicrobial tests showed similar inhibition of E. coli growth 
within 4 h after treatment, using free tetracycline, tetracycline loaded in the small MS and 
tetracycline loaded in the large MS. However, after 4 h and up to 24 h, both tetracycline-
loaded MS exhibited greater inhibition on bacteria growth than free tetracycline. MS NPs 
loaded with tetracycline were also prepared by Sujitha and co-workers and its antibacterial 
activity against S. aureus and E. coli was tested.
[166]
 The prepared tetracycline loaded NPs 
were able to inhibit the growth of S. aureus and E.coli in inhibition zone assays being more 
effective for the gram negative bacteria. 
Yan and co-workers prepared amine-functionalized hollow MS NPs with efficient 
antibacterial (and anticancer) effects.
[167]
 The nanoparticles loaded with isoniazid (INH) (an 
ant-tuberculosis agent) exhibited excellent killing efficiency against Mycobacteria (M. 
smegmatis strain mc
2
 651). The material in PBS at pH 6.6 reached a drug release of ∼60% 
after 72 h. Colony counting antimicrobial tests were used to evaluate the antibacterial effect of 
free INH and INH-loaded hollow MS against M. smegmatis mc
2
 651 over 72 h. Free INH-






INH-loaded MS treated Mycobacteria were completely inhibited at the concentration of 640 
and 320 μg mL
-1
, for 24 and 72 h incubation respectively. This enhanced antibacterial activity 
was attributed to increased intrabacterial accumulation of INH delivered from the hollow MS 
and partly by the strong interactions between the MS and bacteria.  
Yan, Ramström and co-workers also prepared INH-loaded MS NPs in this case additionally 
functionalized with α,α-trehalose through azide-mediated surface photoligation for the 




 The nanomaterial showed increased ability 
to kill bacteria, displaying the advantageous target function of trehalose to facilitate the 
localized release of INH, with a complete growth inhibition within 3−4 mg mL
-1
. Indeed, 
trehalose exists as both free form in the cytosol of mycobacteria and as glycolipids in the cell 
wall,
[169]
 constituting a great target molecule for this bacterial genus. The targeted MS-based 
delivery system showed an eightfold improvement in the antibacterial activity towards 
mycobacteria as compared to the free drug, demonstrating the ability of the targeting ligand to 
selectively target these bacterial cells. 
Alhabardi prepared MS NPs loaded with amoxicillin and erythromycin and tested its 
antibacterial behavior against S. aureus and E. Coli.
[170]
 Both nanoparticles were able to 
inhibit the growth of S. aureus. However, only erythromycin-loaded nanoparticles effectively 
inhibited E. coli growth. The authors suggested that the inability of amoxicillin-loaded NPs to 
kill the gram negative E. coli was due to the small amount of drug released from the MS. 
Film-, platelet-, sphere-, and rod-like MS NPs synthesized by varying the mole ratio of 
cationic surfactant templates, cetyltrimethylammonium bromide (CTAB) and 
tetrabutylammonium iodide (TBAI), were developed by Yan and co-workers.
[171]
 The release 
profiles of CTAB and TBAI from differently shaped materials were determined by 
suspending equal quantities of each material in PBS (pH 7.4) over 48 h. Colony counting 
antimicrobial test was used to evaluate MS behavior against M. smegmatis strain mc
2
 651. 




M. smegmatis, and completely inhibited the formation of colonies at a concentration as low as 
25 μg mL
-1 
after 48 h treatment.  
In addition to the use of small molecules as antimicrobials Yu and co-workers prepared small- 
and large-pore dendritic MS NPs loaded with the antimicrobial enzyme lysozyme.
[172]
 MS 
with a smaller pore size showed a burst release of 100% of the lysozyme within 2 h, which 
was attributed to the surface adsorption of lysozyme. In contrast, MS with a large pore size 
exhibited sustained release patterns with about 67% of lysozyme released within 48 h. 
Besides, lysozyme loaded into MS with a large pore size showed significantly better 
antibacterial activity (MIC value of 500 μg mL
-1
) compared to the NPs with a smaller pore 
size. The optimized MS loaded with lysozyme exhibited total inhibition towards E. coli 
throughout five days.  
Thompson
 
and co-workers developed effective delivery of allyl isothiocyanate (AIT) and 
cinnamaldehyde (CNAD) by using MS NPs for treating biofilms.
[173]
 The release of both AIT 
and CNAD from MS, showed a high initial rate over the first hour due to the steep 
concentration gradient established from within and outside the pores in the external solution 
or due to release of compounds adsorbed on the external surface of the NPs. Subsequently, 
there was a slight and gradual decrease in concentration in the solution from 1 to 24 h for both 
compounds due to their highly volatility. Besides, AIT and CNAD demonstrated increase 
antimicrobial activity against E. coli when packaged into MS NPs than in free forms. IC50 for 
CNAD-loaded MS NPs was around 2 μg mL
-1
, while IC50 for AIT-loaded MS NPs was 1 μg 
mL
-1
. The authors also found that the biocide-loaded NPs showed activity against P. 
aeruginosa biofilms that have inherent resistance to antimicrobial agents. 
Chakravortty, Raichur and co-workers developed MS nanocarriers functionalized with 
arginine and loaded with an antibiotic for targeting and treatment of intracellular 
Salmonella.
[174]
 The arginine based nanocarrier system was developed using a layer-by-layer 




cationic polymer protamine and subsequently with the negatively charged pectin 
polyelectrolyte to form a shell of oppositely charged polyelectrolyte layers. The 
polyelectrolyte-coated MS was decorated with L-arginine (to target intracellular Salmonela) 
by conjugation with the exterior pectin layer. Ciprofloxacin, a fluoroquinolone antibiotic, was 
additionally entrapped in the pores of the NPs. Ciprofloxacin was gradually released over a 
period of 24 h from the NPs in PBS at neutral pH. In vitro antibacterial activity of 
ciprofloxacin-loaded MS was compared with free ciprofloxacin on S. typhimurium; the 
ciprofloxacin-loaded MS exhibited two-fold higher antibacterial activity. The increased 
antibacterial activity of ciprofloxacin-loaded MS was in line with the co-localization of the 
NPs with the intravacuolar Salmonella and localized delivery of the antibiotic. Besides, in 
vivo bacterial burden and morbidity studies in BALB/c mice exhibited nearly ten-fold lower 
Salmonella burden in infected organs such as spleen, liver and mesenteric lymph nodes. 
Similar survival rates were observed at a lower dosage of ciprofloxacin-loaded MS than when 
using free ciprofloxacin.  
Different MS NPs having various particle morphologies, including spheres, ellipsoids, rods, 
and tubes, for controlled release of antibacterial ionic liquids (i.e  1-tetradecyl-3-
methylimidazolium bromide (C14MIMBr), 1-hexadecyl-3-methylimidazolium bromide 
(C16MIMBr), 1-octadecyl-3-methylimidazolium bromide (C18MIMBr), and 1-
tetradecyloxymethyl-3-methylimidazolium chloride (C14OCMIMCl)) were described by Lin 
and co-workers.
[175] 
Delivery of the ionic liquids from MS was governed by the particle and 
pore morphology. Besides, antibacterial activities against E. coli of ellipsoids C16MIMBr-MS 
and tubes C14OCMIMCl-MS, measured over 48 h showed higher activity for the former. The 
mechanism of the antibacterial activity of ellipsoids C16MIMBr-MS was attributed to the 
electrostatic interaction of phosphate groups on the microbial cell wall and the cationic 
methylimidazolium head group of the ionic liquid. The pronounced difference in antibacterial 




C16MIMBr-MS has hexagonal array of ordered pores that all line up parallel allowing faster 
release, while tubes C14OCMIM-MS has a disordered pore arrangement.  
Portolés, Vallet-Regí and co-workers developed different mesoporous microparticles loaded 
with levofloxacin using different drug-loading methods, i.e. impregnation (IP) and surfactant-
assisted drug loading, also denoted as one-pot (OP).
[176] 
Surfactant-free (calcined) and 
surfactant-templated (non-calcined) MS were used for IP and OP starting materials, 
respectively. Flow cytometry studies showed that IP and OP MS did not exert any cytotoxic 
effect on osteoblasts, however, OP induced on fibroblasts a significant proliferation delay 
with morphological alterations and intracellular calcium content but without cell lysis or 
apoptosis. Moreover, both IP and OP MS loaded with levofloxacin, exhibited similar drug 
release profiles. Release studies showed an initial fast delivery followed by a sustained release 
during 13 days. For antibacterial activity studies, IP and OP MS loaded with levofloxacin 
were incubated with E. coli. Bactericidal effectiveness was observed for 14 days for the 
material loaded by IP and for 5 days for the material loaded by OP. 
MS particles loaded with PA-824 (a hydrophobic bactericidal agent) and moxifloxacin were 
prepared and their effect in macrophages infected with M. tuberculosis tested.
[177] 
For this 
purpose, Raw 264.7 macrophages were infected with M. tuberculosis and then were incubated 
with the loaded MS particles for 5 days. Both loaded particles were able to induce a reduction 
in M. tuberculosis population. Encapsulated PA-824 reached the highest antibacterial activity 
at a concentration of 3.33 g mL
-1
. On the other hand, the highest antibacterial activity for 
encapsulated moxifloxacin is 1.11 g mL
-1
. Besides, EC50 values were 1.03 and 0.88 g mL
-1 
for the particles loaded with PA-824 and moxifloxacin, respectively. 
Tailored silica nanoparticles functionalized with (3-aminopropyl)triethoxysilane (APTES) and 
loaded with curcumin were prepared by Cardoso and co-workers.
[178]
 The bactericidal 
properties of these materials were tested against E. coli showing higher effect when the silica 




(silica functionalized with APTES but without curcumin or silica loaded with curcumin 
without APTES). The bactericidal activity of the materials was evaluated by counting the 
number of colonies formed on E. coli Agar plates. The antibacterial effect of silica 
nanoparticles functionalized with APTES and loaded with curcumin was justified due to (i) 
the electrostatic attraction between the positively charged of the amino groups and the 
negatively charged bacteria membrane, and (ii) the curcumin drug effectively loaded into the 
mesoporous silica. 
Raichur and co-workers used MS NPs loaded with ciprofloxacin and coated with a lipid 
bilayer of 1,2-dipalmytoil-sn-glycero-phosphocholine, for the elimination of S. 
Typhimurium.
[179]
 Lipid-coated nanoparticles showed a moderate ciprofloxacin release at 
neutral pH (30% after 30 min) whereas at pH 2.5 a more marked release of the drug was 
observed (probably due to an increase in its solubility at acidic pH). Besides, MTT viability 
assays carried out in RAW 264.7 cells indicated that the system was not toxic. The NPs (at 50 
g mL
-1 
concentration) effectively killed S. typhimurium in RAW 264.7 and HeLa cells 
infected with the bacteria. Also, lipid coated nanoparticles were used for the treatment of mice 
infected with S. typhimurium with remarkable results. For this purpose, S. typhimurium was 
administered orally to mice and then treated with nanoparticles (10 mg kg
-1
 given orally twice 
a day for three days). The treated mice were able to survive till 15 days post infection.  
Xiao and co-workers prepared a multifunctional nanoplatform based on MS NPs for imaging 
guided chemo/photodynamic synergetic therapy (Figure 5).
[180]
 In a first step, carbon dots (C-
dots) were prepared and then embedded in MS NPs (MS@C-dots). Then, Rose Bengal (RB, a 
photosensitizer) was adsorbed onto the MS@C-dots to form MS@C-dots/RB nanoparticles, 
in which C-dots served as a fluorescence probe to achieve cell fluorescence imaging and RB 
generated singlet oxygen to perform photodynamic therapy (PDT). A remarkable 
chemo/photodynamic synergistic anti-tumor effect was achieved with MS@C-dots/RB 




MS@C-dots/RB nanoparticles showed a significant bacterial inhibitory effect against E. coli. 
Photographs of E. coli colonies grown on agar plates showed bacterial inhibition with 
increasing concentrations of MSN@C-dots/RB. 100 mg mL
-1
 of particles inhibited E. coli 
growth over 12 h under green light irradiation. Besides, a significant bacterial inhibitory effect 
against E. coli was also achieved using MSNs@C-dots/RB nanoparticles loaded with 
ampicillin without light irradiation due to ampicillin delivery.  
Anirudhan and co-workers prepared MS NPs loaded with amoxicillin and thiamine 
hydrochloride and coated with chitosan.
[181] 
In a first step, mesoporous silica nanoparticles 
containing cyanopropyl moieties were prepared using the co-condensation method. Then, the 
cyano moieties were oxidized to carboxylic acids by treatment with sulfuric acid. The pores of 
the carboxylic acid-functionalized NPs were loaded with thiamine hydrochloride. Afterward, 
chitosan was grafted onto the external surface of the nanoparticles by the formation of amide 
linkages using EDC. Then, the chitosan layer was modified with a polymer formed by free 
radical graft copolymerization using methacrylic acid, itaconic acid and ethylene glycol 
dimethacrylate as crosslinker agent. Finally, amoxicillin was adsorbed onto the structure of 
the final nanoparticles. Inhibitory zone assays carried out with the prepared nanoparticles and 
E. coli and S. aureus bacteria showed only moderate E. coli growth inhibition (MIC of 50 g 
mL
-1
) as consequence of amoxicillin release. 
Apart of the examples described above, SBA-15 supports (functionalized and un-
functionalised on the surface) have also been used for loading different antimicrobials that 
were delivered by simple diffusion from the mesopores. Malmsten and co-workers prepared 
bare and mercaptopropyl-functionalized SBA-15 MS monoliths whose pores were loaded 
with chlorhexidine or with the antimicrobial peptide LL-37 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES).
[182]
 The four prepared materials 
released, in a sustainable form, chlorhexidine and LL-37 (maximum release achieved after 




their hydrophobic internal surface, when compared to the un-functionalized material. The four 





. However, when higher concentrations of bacteria were used (1.0 x 10
6
), only 
materials loaded with chlorhexidine were efficient. The authors ascribed this fact to the 
incomplete release of LL-37 peptide from the monoliths. 
Vallet-Regí and co-workers prepared SBA-15 disks loaded with vancomycin, rifampicin and 
with a combination of the two drugs and studied the antimicrobial features of the materials 
against biofilms of S. aureus and S. Epidermidis.
[183] 
After 6 h of incubation, the three 
materials were able to induce reduction in the biofilms density for both bacteria. However, the 
observed reduction was more marked for S. epidermidis than for S. aureus. At longer times 
(24 h) the materials loaded with vancomycin and with both drugs showed a marked 
antimicrobial activity for S. aureus and S. epidermidis. 
Hua and co-workers prepared a silica nanocomposite loaded with human bone morphogenic 
protein-2 (rhBMP-2) and tested against E. coli and S. Aureus.
[184] 
In a first step, mesoporous 
SBA-15 NPs were prepared using Pluronic P123 as structure directing agent. Then, the NPs, 
zein (a water insoluble storage protein found in corn), and hydroxypropyltrimethyl 
ammonium chloride chitosan were mixed and transformed onto a nanocomposite using a 
solvent casting-particulate leaching procedure. Finally, rhBMP-2 was loaded upon dropwise 
addition onto the nanocomposites. The prepared system showed a long-term antibacterial 
activity against E. coli and S. aureus with marked inhibitions from day 1 to day 28. This 
antibacterial activity was ascribed to the sustainable release of rhBMP-2 protein from the 
scaffold. Besides, the prepared scaffolds are biocompatible and induced early osteogenic 
differentiation in vitro and ectopic ossification in vivo.  
Vallet-Regí and co-workers used a co-condensation route to functionalize SBA-15 with 
primary and secondary amine groups.
[185] 
The tests against S. aureus demonstrated that the 




compared to pure SBA-15 (both materials in the form of disk-shaped pieces of 6 mm diameter 
and 1 mm height prepared by compacting fractions of 20 mg of the dried powders). Loading 
and release assays using cephalexin as a model antibiotic proved that amine-functionalized 
SBA-15 can release the cargo over long time periods (more than 15 days) compared to pure 
SBA-15. Agar disk-diffusion tests with S. aureus were also performed. Cephalexin-free 
samples did not provoke inhibition zones during the test, which accounts for their lack of 
bactericidal effect. In contrast, well-defined inhibition zones were observed in the assays with 
the cephalexin-loaded materials. 
Grumezescu and co-workers prepared MS of ca. 200 nm diameter loaded with eucalyptus, 
orange and cinnamon essential oils
[186]
 and the antimicrobial properties of the nanoparticles 
were tested against S. aureus, E. coli and C. albicans. The most efficient NPs against S. 
aureus were those loaded with orange essential oil (MIC of 0.37 g mL
-1
) whereas those 
containing cinnamon were the most efficient for E.coli (MIC of 2.5 g mL
-1
). In addition, the 
highest activity toward the yeast C. albicans was observed for the NPs loaded with eucalyptus 
essential oil (MIC of 0.18 g mL
-1
). Besides, NPs loaded with the three essential oils showed 
a marked inhibitory effect toward the formation of S. aureus and E. coli biofilms. NPs loaded 
with orange essential oil showed the highest inhibitory effect in C. albicans biofilms. The 
authors also tested the biocompatibility of the prepared NPs using the MTT assay with L929 




Shchukin and co-workers loaded MCM-48 NPs (400 nm diameter), with the biocide parmetol 
S15, and additionally functionalized the external surface with the bactericidal derivatives 
dimethyloctadecyl[3-(triethoxysilyl)propyl]ammonium chloride and dimethyltetradecyl[3-
(triethoxysilyl)propyl]ammonium chloride.
[187] 
Unloaded materials were able to reduce 




with octadecyl groups more effective due to the presence of longer alkyl chains that 
penetrated easily in the bacteria membrane. Besides, the nanoparticles loaded with parmetol 
S15 presented 100% reduction after 3 h for both E. coli and S. aureus.  
Some MS particles combined with magnetic nanoparticles have also been reported for the 
efficient capture and elimination of bacteria. For instance, magnetic Janus nanorods for the 
efficient capture, separation and elimination of bacteria were prepared by Dong and co-
workers.
[188] 
These Janus nanodevices consisted of a Fe3O4 head (nanoparticles of 100 nm 
diameter) and a mesoporous silica rod (200 nm length) with the surfactant CTAB in the inner 
of the pores and aminopropyl moieties grafted onto the external surface. The prepared Janus 
nanorods could capture and separate E. coli and S. aureus by using an external magnet. The 
capture was a direct consequence of electrostatic interactions between the positively charged 
silica nanorod and the negatively charged surface of the bacteria. The efficiency of the capture 
process reached 90.1 and 85.4% for E. coli and S. aureus respectively. Besides, using a 
concentration of nanorods of 50 g mL
-1 
the measured antibacterial efficiencies for E. coli and 
S. aureus were 95.9 and 73.6% respectively. The use of 100 g mL
-1
 of Janus nanorods 
inhibited completely bacterial growth.  
Fang and co-workers also prepared Fe3O4 magnetic NPs coated with a MS shell containing 
CTAB in the pores.
[189] 
When the concentration of the prepared nanoparticles was set at 50 g 
mL
-1
, remarkable inhibition growths for E. coli (98%) and B. subtilis (97%) were observed 
after 24 h of incubation. Besides, the authors showed that magnetic nanoparticles could be 
efficiently used for bacteria capture and separation by using a magnet. 
Faivre, Sitti and Sánchez prepared magnetotactic bacteria powered biohybrids targeting E. 
coli biofilms.
[190] 
The nonpathogenic magnetotactic bacteria Magnetosopirrillum 
gryphiswalense (MSR-1) was adhered inside ciprofloxacin-loaded MS microtubes, to build 




external magnetic guidance the biohybrids were directed and pushed into matured E. coli 
biofilms, showing high antibacterial efficacy due to effective ciprofloxacin delivery. The 
solubility of ciprofloxacin in aqueous solutions is pH dependent, and in this context 
ciprofloxacin release was triggered by the acidic microenvironment at pH 5.8 of the biofilm. 
At pH 7.4, almost no ciprofloxacin was released from the tubes over 24 h. 
Examples above are based in the use of MS that allowed a targeted or untargeted delivery of a 
certain bactericidal. Moreover, more advanced systems in which MS are incorporated in films, 
hydrogels, fabrics, and bone implants have also been prepared. Thus, Shen and co-workers 
prepared titanium films coated with an antibacterial MS layer, which could be used as implant 
material.
[191] 
The pores of the MS coating were loaded with heparin and vancomycin. When 
the prepared films were dipped onto a PBS solution, vancomycin and heparin were 
simultaneously released reaching a maximum value of 400 and 700 g of drugs per cm
2
 of 
film respectively (after 30 days). The prepared films presented high levels of viability with rat 
osteoblasts. Besides, the prepared films were able to inhibit the growth and adhesion of S. 
aureus and E. coli due to the release of the entrapped heparin and vancomycin. In a closely 
related approach, the same authors prepared silicone films functionalized with aminopropyl 
moieties and adsorbed, through electrostatic interactions, MS NPs loaded with agarose and 
heparin.
[192] 
The prepared materials were able to release heparin when introduced into a PBS 
solution (40% of delivery after 1 day). The films presented remarkable antifouling properties 
against red blood cells, platelets, fibrinogen and bacteria (E. coli and S. aureus). The 
inhibition of bacterial adhesion was ascribed to the improved surface hydrophilicity imparted 
by the agarose loading. 
Xu, Cai and co-workers coated titanium disks with MS NPs using an electrophoretic-
enhanced micro-arc oxidation procedures. The MS NPs were loaded with the antiseptic agent 
octenidine dyhidrochloride.
[193] 
A marked reduction in bacterial adhesion (E. coli and S. 




when the MS-coated disks without any cargo were used. The authors ascribed the reduction in 
bacterial adhesion to the release of octenidine dyhidrochloride. This compound was inserted 
into the bacteria walls, through electrostatic interactions, breaking down the integrity of 
bacteria. 
Huang and co-workers prepared hydroxyapatite-MS materials loaded with epigallocatechin-3-
gallate for the therapeutic elimination of Streptococcus mutants biofilms.
[194] 
UV-visible 
measurements indicated that epigallocatechin-3-gallate was released from the material in a 
sustainable fashion over 96 h. Besides, MTT viability assays carried out with the 
nanocomposite showed non-toxicity for human dental pulp stem cells. Dentin tubules were 
filled with the prepared bio-nanocomposite and a marked S. mutans biofilms inhibition was 
observed due to the release of epigallocatechin-3-gallate. 
He and co-workers developed an organic–inorganic hybrid hemostatic material by 
incorporating curcumin-loaded MS NPs into polyvinyl pyrrolidone (PVP) nanofiber mats by 
electrospinning.
[195] 
In vitro cytotoxic studies demonstrated that the hybrid nanofiber mats had 
no obvious toxic effect on the growth of murine L929 fibrosarcoma cells. Moreover, the 
hybrid nanofiber mats exhibited enhanced in vitro antibacterial effect against methicillin-
resistant S. aureus due to the delivery of the loaded curcumin. Furthermore, an in vivo liver 
injury model for hemostasis studies revealed that the hybrid nanofiber mats rapidly transform 
into hydrogel when in contact with blood, and activate the clotting system to stop wound 
bleeding. This provides an example of nanofiber-based hemostatic materials with good 
biocompatibility and high antibacterial activity. 
MS SBA-15 particles have also been used for the preparation of more complex composites of 
potential applications by its incorporation in fabrics and in dental composites. Thus, SBA-15 
NPs, functionalized with 3-aminopropyl moieties and loaded with betamethasone sodium 
phosphate, were grafted onto a cotton fabric surface using chitosan and polysiloxane.
[196] 
The 




an addition reaction of the silanol moieties of the MS with the epoxide groups of the 
polysiloxane. The growth of E. coli and S. aureus strains was remarkably reduced in the 
cotton fabric samples containing the loaded SBA-15 particles (99.9 and 99.4% reduction for E. 
coli and S. aureus respectively). In addition, Xu and co-workers developed an antibacterial 
dental composite against S. mutans and Lactobacillus casei containing chlorhexidine 
encapsulated in SBA-15.
[197] 
For the preparation of the composite, in a first step, the pores of 
the SBA-15 were loaded with chlorhexidine. Then, the loaded nanoparticles were mixed with 
bisphenol A glycidyl methacrylate, hexanediol dimethacrylate, ethoxylated bisphenol A 
dimethacrylate, urethane dimethacrylate and a photo-initiator (camphorquinone: phenyl 
bis(2,4,6-trimethyl benzoyl)phosphine oxide: ethyl 4-dimethylaminobenzoate). Irradiation 
with a visible light yielded the final composite. Upon immersion of the prepared 
nanocomposite in water at 37 ºC a sustainable release of chlorhexidine over a long time 
period was observed. The antibacterial efficacy of the composite was evaluated using two 
methods: planktonic bacterial growth and biofilm tests. Both assays showed strong inhibition 
against S. mutans and L. casei by the SBA-15-containing composite. 
In a system for applications in bone-implant technology, Grumezescu and co-workers used 
matrix assisted pulsed laser evaporation to deposit thin coatings of MS NPs loaded with the 
antibiotic Zinforo (ceftarolinum fosmil) at the bone-implant interface.
[198] 
Microbiological 
analyses performed on Zinforo-loaded films against E. coli demonstrated a decrease of the 
microbial adherence and colonization of the surface for 72 h. Moreover, in vitro MTT assays 
showed no-cytotoxicity of the Zinforo-loaded thin coatings against endothelial EAhy926 cells 
over 72 h. Besides, in vivo assays were carried out with mice intraperitoneally inoculated in 
the groin area with the Zinforo-loaded MS nanoparticles, providing the excellent 
biodistribution and biocompatibility. At 7 and 14 days after inoculation mice were killed and 
the different tissues fixed in paraffin. The subsequent histological evaluation showed than 




Santamaría and co-workers prepared hollow porous medical grade stainless steel pin implants 
filled with MCM-48 microparticles for linezolid release.
[199] 
In a first step, MCM-48 
microparticles were prepared and their pores loaded with linezolid. Then, the linezolid-loaded 
microparticles were packed inside of a porous stainless steel pin. This nanodevice was able to 
release, for 6 days, the loaded linezolid upon its immersion in simulated body fluid at 37 ºC. 
Besides, the prepared stainless steel pin was able to reduce S. aureus growth up to 3 orders of 
magnitude after 48 h when compared with a similar nanodevice packed with empty MCM-48 
microparticles. 
Behrens and co-workers prepared MS coatings for the release of ciprofloxacin from implants 
to prevent bacterial infection.
[200] 
The authors prepared three different MS coated supports. 
For this purpose, and in a first step, a glass substrate was coated with a MS layer. Then, the 
silica layer was functionalized with mercaptopropyl units and, afterward, the thiol groups 
were oxidized to sulfonic acids using hydrogen peroxide. The pores were finally loaded with 
ciprofloxacin (material A). Moreover, the pores of the loaded substrate were capped by dip-
coating using bis(trimethoxysilyl)hexane, yielding material B. Finally, for the preparation of 
material C, the capping layer was further treated with dioctyltetramethyldisilazane. The three 
materials, when submerged in PBS, where able to release the entrapped drug at a constant rate 
during several days (12, 30 and 63 for materials A, B and C respectively). Besides, the three 
materials released a similar amount of ciprofloxacin (ca. 2 g cm
-2
).  The authors found that 
the three prepared materials were able to inhibit the growth of P. aeruginosa for up to ten 
days being the uncapped glass the most effective. 
Vallet-Regí and co-workers developed multifunctional pH sensitive 3D scaffolds for 
treatment and prevention of bone infection
.[201] 
The hierarchical meso-macroporous 3D 
scaffolds consisted of a mesostructured SiO2–CaO–P2O5 glass wall with embedded 
hydroxyapatite nanoparticles, whose mesopores were loaded with levofloxacin. These 3D 




physiological pH (7.4), which notably increased at pH 6.7 and 5.5. This was attributed to the 
different interaction between levofloxacin species and the silica matrix. 3D scaffolds were 
able to inhibit the S. aureus growth over 15 days and to destroy the bacterial biofilm. 
Furthermore, in vitro co-culture studies showed no cytotoxic effects of the scaffold on 
MC3T3-E1 cells, a murine calvaria-derived pre-osteoblastic cell line. Besides, the scaffold 
showed biocompatibility on human osteosarcoma Saos-2 cell line. 
Jin and co-workers loaded the pores of MS nanoparticles with chlorhexidine and studied the 
antibacterial activity of the loaded material against several biofilms.
[202]
 The prepared 
chlorhexidine-loaded nanoparticles were able to release the entrapped antibiotic in a 
sustainable fashion for 72 h reaching the maximum delivery after 6 h. The prepared 
nanoparticles showed a marked antibacterial effect and were able to inhibit bacterial biofilms 
of S. mutans, S. sobrinus, F. nucleatum, A. actinomycetemcomitans and E. faecalis with MICs 
of 100, 200, 100, 100 and 200 μg mL
-1
, respectively. Besides, nanoparticles were also able to 
inhibit growth of mixed biofilms. At this respect, for biofilms of S. mutans, F. nucleatum and 
P. gingivalis the MIC after 24 h was 12.5 μg mL
-1 
whereas for S. sobrinus, F. nucleatum and 
P. gingivalis MIC was 25 μg mL
-1 
after the same time period. Finally, for a biofilm of 4 
bacteria (S. mutans, F. nucleatum, A. actinomycetemcomitans and P. gingivalis) the measured 
MIC was 25 μg mL
-1 
after 24 h. 
MS nanoparticles loaded with gentamicin were deposited onto thin films and its antibacterial 
performance was tested against S. aureus biofilms.
[203]
 For the preparation of the final thin 
films, quartz slides were coated with polyelectrolyte layers of polyehtyleneimine and 
polystyrene sulfonate-polyallylamine. Then, gentamicin-loaded MS nanoparticles were 
deposited onto the polyelectrolyte layers and finally a protective outer nafion layer was 
applied. Inhibition zone experiments, carried out with the prepared thin films and S. aureus 
and S. pneumoniae, showed marked antibacterial effects due to the sustained gentamicin 




Besides, the prepared films were able to inhibit the growth of S. aureus biofilms and 
negligible bacterial attachment onto the external surface of the films was observed by 
confocal laser scanning microscopy measurements after 2 months.  
 
3.3. Gated MS loaded with antimicrobial agents 
As explained above gated MS are nanodevices which are able to release an entrapped cargo at 
will upon application of selected external stimuli. Gated MS have been used for the controlled 
released of drugs in nanomedice applications,
[102]
 as new sensory materials
[113] 
and, very 
recently, in abiotic communication processes,
[107] 
however gated MS in bactericidal 
applications have been scarcely used. Examples of gated MS able to release an entrapped 
antimicrobial in the presence of bacteria, pH changes, enzymes, certain chemical species, 
temperature and light have been described. 
Some examples of antimicrobial gated MS were able to release its entrapped cargo in the 
presence of bacteria by simple detachment of the capping molecules upon interaction with the 
bacterial wall. Following this approach Martínez-Máñez and co-workers enhanced the 
efficacy and broadening of antibacterial action of drugs.
[204] 
The nanodevice was based in MS 
NPs loaded with vancomycin (MS-Van). Then, the external surface of the loaded support was 
functionalized with N-[(3-trimethoxysilyl) propyl]ethylendiamine triacetic acid trisodium salt 
and capped, through electrostatic interactions, with the cationic polymer-poly-L-lysine (-
PL). MS-Van was used as antimicrobial agent against E. coli, Salmonella typhi and Erwinia 
carotovora. Moreover, using a similar procedure, MS nanoparticles loaded with rhodamine B 
and capped with -PL were prepared (MS-Rho) and in vitro dye-release studies were carried 
out (see Figure 6). Dye delivery from MS-Rho was studied in the presence and absence of 
E.coli. In the absence of E. coli negligible dye release was observed, indicating that the NPs 
were tightly capped. In contrast, in the presence of bacteria the uncapping of the pores was 




with the negatively charged bacterial wall, which resulted in cargo delivery. Moreover, the 
effect on bacterial cell integrity by clonogenic cell-viability assays was carried out with bare 
MS nanoparticles, free vancomycin, free -PL, free -PL/vancomycin, MS-Rho and MS-Van. 
A remarkable enhancement of the toxicity of -PL and vancomycin in MS-Van was found 
against E. coli. For instance, MS-Van exhibited a noteworthy six-fold decrease in MIC (2.89 
g -PL mL
-1
) when compared to that of MS-Rho (16.7 mg -PL/mL). Furthermore, 
antimicrobial activity of the solid MS-Van against E. coli 405, Salmonella typhi and Erwinia 
carotovora was also carried out. The obtained results indicated a strong inhibition of bacterial 
growth and a large synergistic effect (due to the release of both -PL and vancomycin) when 
this nanoformulation was used. 
Using a similar approach, Velikova and co-workers prepared different gated MS NPs loaded 
with histidine kinase autophosphorylation inhibitors (HKAIs). Pores of the loaded support 
were again functionalized with N-[(3-trimethoxysilyl) propyl]ethylendiamine triacetic acid 
trisodium salt and capped with -PL.
[205] 
Antimicrobial tests using the prepared nanoparticles 
against E. coli and Serratia marcescens showed higher activity that free HKAIs. As before, 
the mechanism of action of the particles was attributed to the interaction of the positively 
charged capped-MS with the negatively charged E. coli bacterial cell wall, and displacement 
of the capping -PL, which resulted in release of the loaded HKAIs and subsequent inhibition 
of bacteria growth. Moreover, cytotoxic assays showed no adverse effects of the particles on 
mammalian cells or on the immune function of macrophages, and showed no signs of toxicity 
to zebrafish larvae in vivo. 
Colloidal gold nanoclusters spiked silica fillers in mixed matrix coatings for detection and 
inhibition of healthcare-associated infections were prepared by Khashab and co-workers.
[206] 
The authors developed an antibacterial polymer coating containing gold nanoclusters-




applied on a medical device for safer X-ray dental imaging. The electrostatic self-assembly of 
negatively charged and fluorescent AuNCs onto positively charged aminated MS provided a 
bacteria responsive system. Upon encountering bacteria, AuNC@Lys detached from the MS 
NPs surface due to the interaction of lysozyme with the bacterial cell wall, and the release of 
the entrapped Kana antibacterial occurred. This mixed-matrix coating was able to detect 
bacteria growth on a common radiographic dental imaging device (photostimulable phosphor 
plate) by evaluating the variation and eventually disappearance of the red fluorescence surface 
of AuNC@Lys under UV light. Besides, the controlled release of Kana from the coating by E. 
coli was studied over 3 h. Decreased of the viability of E. coli by 50% in only 50 min, and by 
about 80% in 170 min was observed. The system was also very effective toward the Gram+ 
Bacillus safensis (B. safensis). 
Other stimulus used to uncap antibacterial nanodevices is pH changes. For instance, Qu and 
co-workers prepared a “sense-and-treat” hydrogel, which contained MS NPs, for detection 
and elimination of bacteria.
[207]  
For this purpose, MS NPs were loaded with vancomycin and 
the external surface functionalized with fluorescein isothiocyanate (FITC). Afterwards, the 
pH-sensitive polymer poly(N-isopropyl acrylamide-co-acrylic acid) was copolymerized with a 
rhodamine B derivative functionalized with an acrylamide moiety (RhBAM). The obtained 
copolymer was then grafted onto the MS scaffold as a “gatekeeper” to control drug release 
(see Figure 7). In this context, FITC and RhBAM made up a ratiometric fluorescence probe. 
The nanoparticles had a strong emission at 518 nm in basic or neutral pH, whereas the 
emission was reduced at acidic pH, because of the pH-sensitive properties of FITC. Moreover, 
the RhBAM moiety existed in the spirolactam form at basic pH and exhibited no fluorescence, 
whereas at acidic pH it was transformed into the “open” form and emitted a strong 
fluorescence at 575 nm. According to the aforementioned principles, the protons produced by 
bacteria caused a fluorescence change of the pH sensitive hydrogel and also triggered 




release studies from the MS NPs without RhBAM were compared with vancomycin release 
studies from the MS NPs with RhBAM at different pH over 12 h. Release studies showed 
higher vancomycin release at acidic pH from the MS NPs with RhBAM. In contrast, for the 
MS NPs without RhBAM, drug release showed similar profiles at different pHs. Furthermore, 
the presence of E. coli was evaluated using MS-hydrogel (280 μg mL
-1
), showing high 
antimicrobial activity over 36 h.  
Li and co-workers used Fe(III)-carbenicillin  (a -lactam antibiotic) metal organic framework 
(carMOF) as capping unit for the development of a nanodevice with enhanced penetration and 
highly efficient inhibition of methicillin-resistant S. aureus (MRSA).
[208] 
MS NPs were loaded 
with sulbactam (sul-MS), a -lactamase inhibitor, and then the external surface coated with 
carMOF (carMOF-sul-MS, Figure 8). Drug release (carbenicillin and sulbactam) from 
carMOF-sul-MS was carried out at pH 7.4 and pH 5.0 over 96 h. A higher cargo release was 
observed at pH 5.0, which was consistent with the dissolution of the carMOF in an acidic 
environment. The carMOF-sul-MS nanodevice was able to inhibit MRSA growth at acidic pH 
due to the delivery of carbecillin (from the degraded carMOF) and sulbactam (loaded in the 
pores of sul-MS). Moreover, the final material showed non-toxicity against RAW 264.7 cells 
over 48 h. Besides, in vivo studies showed decreased MRSA infection in the skin of mice 
treated with carMOF-sul-MS. 
 
Physical stimuli (such as temperature) have also been used as external triggers to induce 
antimicrobial release. Using this approach, nanoparticles containing a Fe3O4 core and a MS 
layer, capped with the thermoresponsive poly(N-isopropylacrylamide) (PNIPAM) and loaded 
with a dye or the antibacterial enzyme lysozyme were prepared by Martínez-Máñez and co-
workers (see Figure 9).
[209] 
Both capped-core-shell nanoparticles showed no cargo release at 
25 ºC, whereas abrupt payload delivery was observed at 37 ºC, due to pore opening as the 




were carried out at different temperatures against Bacillus cereus and Micrococcus luteus. 
The results demonstrated that the nanoparticles were not toxic for bacteria at a concentration 
of 0.50 mg mL
-1
 at 25 ºC, whereas delivery of lysozyme at 37 ºC resulted in a remarkable 
reduction of bacteria growth after 24 h, demonstrating that the PNIPAM gates played an 
important role in modulating the release of the lysozyme. 
Capped MS able to release an entrapped cargo in the presence of certain (bio)molecules, 
excreted by bacteria or externally added, have also been described. At this respect, Gao and 
co-workers developed layer-by-layer (LBL) self-assembled bio-hybrid nanomaterials for 
efficient antibacterial applications.
[210] 
For this purpose, MS NPs were loaded with the 
antibiotic amoxicillin and then functionalized with carboxylates onto the external surface of 
the support. Then, positively charged lysozyme was adsorbed onto the external surface of the 
loaded support (through electrostatic interactions) and these nanoparticles were consecutively 
coated with hyaluronic acid (HA) and 1,2-ethanediamine-modified polyglycerol methacrylate 
(PGMA) (see Figure 10). The final systems was designed to release the encapsulated 
antibiotic in the presence of hyaluronidase, an enzyme produced by S. aureus. The authors 
found that the release of loaded amoxicilin was accelerated with the addition of hyaluronidase, 
compared with the control without the enzyme. The antibacterial effect was measured with 
amoxiclin-resistant E. coli and S. aureus with varied concentrations of the NPs. The final 
nanodevice showed better antibacterial effect than that of lysozyme or amoxiciline after 16 h. 
MIC values toward amoxicilin-resistant E. coli and S. aureus were, respectively, 62 μg mL
-1 
and 47 μg mL
-1
, which was much lower than that of free lysozyme (500 μg mL
-1
). The authors 
suggested that the presence of cationic polymers in the NPs provided multivalent interactions 
between the NPs and the bacterial membrane. The antibacterial activity of the NPs was also 
evaluated in vivo, using a mouse wound model infected with S. aureus. Epidermal drug 




bacteria to a bacteriostatic rate of 67.4%, compared to the negative controls, while the 
application of the NPs inhibited completely the bacteria, with a bacteriostatic rate of 99.9%. 
The same authors also prepared a multifunctional material, using the layer-by-layer self-
assembly method, for bacterial detection and inhibition.
[211] 
For the preparation of the material, 
MS were loaded with amoxicillin. Then, the external surface of the nanoparticles was coated 
with 1,2-ethanediamine-modified polyglycerol methacrylate and cucurbit[7]uril (CB7) was 
attached onto the polymeric layer by forming inclusion complexes with the 1,2-ethanediamine 
moieties. Finally, tetraphenylethylene tetracarboxylate was adsorbed, through electrostatic 
interactions, onto the polymeric layer. The prepared nanoparticles were unable to release the 
entrapped amoxicillin when suspended in water at neutral pH. However, in the presence of 
adamantaneamine a marked delivery of the drug was observed. This release was a 
consequence of the formation of a supramolecular inclusion complex between 
adamantaneamine and CB7, which disrupted the assembly, releasing the polymer and 
tetraphenylethylene tetracarboxylate. PBS suspensions of the multifunctional nanoparticles 
were emissive due to the aggregation of tetraphenylethylene tetracarboxylate onto the 
polymeric layer. This emissive feature of the nanoparticles was used to detect E. coli and S. 
aureus because adsorption of both bacteria onto the positively charged polymeric layer 
induced the displacement of tetraphenylethylene tetracarboxylate, which was reflected in a 
marked emission decrease. The prepared nanoparticles presented moderate bacterial killing 
ability with minimum inhibitory concentrations of > 1000 g mL
-1
 for both E. coli and S. 
aureus, whereas in the presence of adamantaneamine the values were lower (125 and 250 g 
mL
-1
 for S. aureus and E. coli respectively). SEM measurements indicated that treatment of E. 
coli and S. aureus with the nanoparticles and adamantaneamine induced marked changes in 
the bacteria membrane morphology. 
Zink and co-workers prepared MS NPs loaded with moxifloxacin and capped with a redox-
sensitive disulfide snap-tops.
[212] 




trimethoxysilane and with adamantanethiol forming a disulfide bond. Then, the solid was 
loaded with moxifloxacin and capped by adding β-CD that formed inclusion complex with the 
grafted adamantanethiol. In reducing environments (e.g., after addition of glutathione or after 
uptake by macrophages), the disulfide bond is cleaved and cargo delivery was observed. 
Furthermore, similar nanoparticles were also loaded with Hoechst fluorescent dye. The 
authors found that the cargo was released intracellularly, staining the nuclei of macrophages 
due to the presence of glutathione in cells. The nanoparticles were able to eliminate 
Francisella tularensis in macrophages. In particular, treatment with the moxifloxacin-loaded 
MS (6.25–400 ng mL
-1
) or moxifloxacin (1–64 ng mL
-1
) reduced bacterial CFU in 
macrophages in a dose dependent manner. In a mouse model of lethal pneumonic tularemia, 
moxifloxacin-loaded MS prevented weight loss, illness and death, markedly reduced the 
burden of F. tularensis in the lung, liver, and spleen, and were significantly more efficacious 
than an equivalent amount of the free drug. 
Vallet-Regí and co-workers prepared “nanoantibiotics” using MS nanoparticles loaded with 
levofloxacin and with their external surface decorated with polycationic dendrimers.
[213]
 
Poly(propylene imine) G3 dendrimer was reacted with (3-isocyanatopropyl) triethoxysilane 
and the external surface of levofloxacin-loaded MS nanoparticles was decorated with the 
trialkoxysilane derivatized dendrimer. PBS suspensions of the prepared nanoparticles at pH 
7.4 showed a marked and sustainable levofloxacin release which follows a first order kinetics 
(100% drug release after 72 h). Confocal microscopy studies, carried out with E.coli, showed 
a complete internalization of the nanodevice and its localization in the cytosol of the bacteria. 
This internalization is a consequence of the positive charge of the external surface of the 
nanodevice that was attracted by the negatively charged bacteria membrane. This binding 
induced slightly changes in membrane permeability allowing nanodevice internalization. 




CFUs for E. coli. Besides, dendrimer-functionalised nanoparticles, at 5 g mL
-1
 concentration, 
induced a marked disruption of E. coli biofilms. 
 
3.4. MS with metal-based NPs  
At present, silver nanoparticles (AgNPs) are considered the best alternative to antibiotics, as 
these nanomaterials exert great toxic effects against a wide range of AMR pathogenic 
organisms without the addition of other compounds.
[214–217]
 AgNPs are already used as 
biomedical additives in bandages, catheters, and in medical garrisons for treating wounds and 
burns.
[29]
 Similarly, metal oxide NPs showed to be effective in killing a variety of bacterial 
pathogens responsible for hospital-acquired infections, even if a higher concentration of this 
formulation was required as compared to AgNPs to obtain the desired antimicrobial activity. 
[218,219]
  
The mechanisms by which metal-based NPs exert their toxic effects upon pathogenic cells 
constitute still a black hole of this research field, as several structural parameters of NPs (e.g., 
composition, surface modification, intrinsic physical properties) can influence their 
antimicrobial activity.
[1] 
Moreover, the intrinsic biodiversity of the existing pathogenic 
microorganisms in their genetic arrangement, cell wall structure, and metabolic pathways 
strongly contributes to increase the complexity in determining the mechanisms of action of 
metal-based NPs.
[4] 
Nevertheless, since NPs can directly act against pathogenic cells by 
contact with the target cell membrane, most of the AMR mechanisms already established for 
antibiotics are inefficient,
[1],[4]
 suggesting that NPs should lead to a low level of resistance 
arising within pathogens.   
One of the antimicrobial effect of metal-based NPs towards pathogens is triggered by the 
electrostatic binding of these nanomaterials to the cellular membranes, causing their 
modification and/or disruption through metal ion release or the physical structure of the NPs 
themselves.
[4] 




integrity by changing its potential and depolarization, therefore causing a transport imbalance 
and an impairment of the respiratory chain, which can in turn lead to cell lysis or cell 
death.
[220] 
In this regard, the antimicrobial efficacy of AgNPs seems to rely on the strong 
affinity between Ag and sulfur (S), nitrogen (N) and even phosphorous (P), which are key 
biochemical elements of the cell.
[29] 
Thus, AgNPs directly interact with S-containing proteins 
of the cellular membrane, affecting the functionality of these macromolecules and, therefore, 
the permeability of the membrane, causing a loss of cell viability.
[221] 
Moreover, it has been 
shown that Ag(I) ions released by a high amount of administered AgNPs can interact with P 






 which is caused by respiratory chain disruption or by the physical-
chemical properties of the NPs themselves.
[227] 
As a consequence of the oxidative stress 
response, Reactive Oxygen Species (ROS) are produced within pathogenic cells,
[228] 
leading 
to severe macromolecular damages (e.g., lipid peroxidation, alteration and inhibitions of 
proteins or enzymes, DNA mutations or RNA damage)
[4]




Although metal-based NPs have shown promising efficacy in inhibiting the growth of AMR 
pathogenic microorganisms, several bacterial strains result to be naturally adapted to specific 
toxins or ions contained in NPs.
[1] 
Indeed, one of the resistance mechanism mostly diffuse in 
AMR bacterial cells is their ability to change the structure and the composition of their cell 
walls in order to become resistant towards antibiotics.
[230] 
Similarly, an increase in the amount 
of saturated fatty acids present in bacterial cell membranes can lead to an increased membrane 
fluidity, conferring to these bacterial cells a high degree of protection from oxidative stress 
caused by metal-based NPs,
[231] 
while the peculiar physical properties of the peptidoglycan 
layer of some Gram-negative bacteria can mediate an efflux mechanism of metal-based 
NPs.
[232,233]




NPs is the rate of cell growth. Indeed, slow-growing bacterial strains are more resistant 
towards these nanocompounds, as one of their features is the greater expression of stress-
response genes compared to fast-growing species.
[1] 
Finally, metal oxide NPs (e.g., CuO or 
ZnO NPs) can be very inefficient as an antimicrobial when administered to bacterial strains 
that are able to produce EPS under stress conditions, as these NPs if adsorbed on the bacterial 
cell surface, can be degraded by specific enzymes.
[1]
 
Most of the examples described in this section contain AgNPs although some examples 
containing Au, ZnO, TiO2, CuO and CdS NPs in MS have also been reported. We will first 
summarize examples containing Ag NPs, whereas at the end of the section examples using 
MS with other metal-based NPs are described. In the synthesis of MS containing AgNPs, in 
most cases Ag(I) ions are added to the MS and then reduced to AgNPs using different 
reducing agents. At this respect, Jiang and co-workers prepared MCM-41 MS NPs 
functionalized with AgNPs and tested their antibacterial activity against E. coli and S. 
Aureus.
[234]
 The authors prepared the silica nanoparticles by the co-condensation method 
using N-(aminoethyl)-amino-propyl trimethoxysilane and tetraethylorthosilicate. Then, silver 
nitrate was added and the Ag(I) ions coordinated with the nitrogen atoms of the grafted 
amino-propyl moieties. Finally, Ag(I) ions were reduced to AgNPs using formalin. The 
AgNPs obtained were well dispersed around the MCM-41 framework and the prepared 
nanocomposite had good biocompatibility. The growth of bacteria was completely inhibited 
using concentrations of nanoparticles of 80 and 320 g mL
-1
 E. coli and S. aureus 
respectively. Besides, the antibacterial activity of the prepared nanoparticles was preserved 
for 30 days. Scanning laser confocal microscopy measurements showed the adsorption of the 
prepared nanoparticles onto the bacterial wall. The authors suggested that sustainable release 





Fu and co-workers prepared MS NPs functionalized with AgNPs and tested their antibacterial 
behavior against E. coli and S. Aureus.
[235] 
The final material was prepared from MS particles 
of ca. 130 nm that were coated with a mesoporous shell containing aminopropyl moieties. 
Silver nitrate was added to a MS suspension and the mixture was treated with ultrasounds for 
2 h. This ultrasonic treatment reduced Ag(I) to AgNPs. The prepared AgNPs-containing MS 
support presented a marked bacterial growth inhibition with MIC of 0.156 and 0.313 mg mL
-1
 
for S. aureus and E. coli respectively.  
Long and co-workers prepared MS nanoparticles decorated with well dispersed AgNPs using 
a co-condensation procedure and N-(aminoethyl)-amino-propyl trimethoxysilane (as coupling 
agent) and silver nitrate (as Ag source). Once prepared, the nanoparticles were deposited onto 
nanofibrous membranes prepared from poly--caprolactone by using a electrospinning 
device.
[236] 
The authors found that nanofibrous membranes were able to inhibit the growth of 
E. coli and S. aureus after 12 h of contact. Besides, these antibacterial membranes were able 
to reduce inflammatory response and accelerate wound healing in Wistar rats. 
Hollow MS NPs have also been used as reservoir for depositing AgNPs.
[237] 
For the 
preparation of the mesoporous scaffold the authors used poly(styrene-co-methyl methacrylate-
co-methacrylic acid) as hollow-structure template and CTAB as mesostructured directing 
agent. The AgNPs were deposited onto the surface of the hollow MS nanoparticles by the n-
butylamine-induced reduction of silver nitrate. Inhibition zone tests indicated that the 
prepared hollow nanoparticles were able to inhibit the growth of S. aureus and E. coli strains. 
Hollow MS microspheres loaded with AgNPs were also prepared by Yang, Shen and co-
workers.
[238] 
The dosage of AgNO3, polyvinylpyrrolidone, tetraethoxysilane and ammonia was 
investigated to explore the variation in the morphology of the prepared materials. Results 
showed that high AgNPs loading and large pore size increased the Ag(I)
 
ion release rate.  
Tang and co-workers prepared hierarchically wrinkled MS NPs loaded with AgNPs and tested 
their antibacterial behavior against E. coli and S. Aureus.
[239] 




scaffold was functionalized with mercaptopropyl moieties. Then, the thiol groups were 
oxidized to sulfonic acid using hydrogen peroxide. Afterward, Ag(I) ions are loaded, through 
electrostatic interactions with the sulfonate moieties, and finally AgNPs were obtained upon 
addition of sodium borohydride. The prepared material presented remarkable antibacterial 
effects. At this respect, MIC of 73.10 and 36.55 g mL
-1 
for S. aureus and E. coli were 
determined. On the other hand, minimal bactericidal concentrations were set at 97.10 and 
48.55 g mL
-1
 for S. aureus and E. coli respectively.  
Chen and co-workers prepared SBA-15 MS microparticles decorated with AgNPs.
[240]
 The 
authors adsorbed dopamine onto the surface of the mesoporous scaffold by electrostatic 
interactions and then silver nitrate was added to coordinate Ag(I) ions with de catechol 
subunit of the dopamine. The suspension at pH 8.5 was heated at 80ºC for 12 h in order to 
reduce Ag(I) ions forming AgNPs. The prepared nanocomposite was able to completely 
inhibit bacterial growth after 12 h for E. coli and after 36 h for S. aureus.  
Zink and co-workers prepared AgNPs (less than 20 nm in diameter) coated with a MS shell 
and studied its antimicrobial behavior against E. coli and B. Anthracis.
[241] 
The authors 
observed that nanoparticles at concentration of 100 g mL
-1
 inhibited completely the 
formation of colonies for B. anthracis. However, the NPs had no effect on E. coli growth. The 
authors prepared another set of nanoparticles by coating the external MS shell with PEI 
polymer (through electrostatic interactions). These PEI-coated nanoparticles, at 100 g mL
-1
, 
were able to induce growth inhibition of both strains due to the fact that positively charged 
NPs surface interacted more efficiently with the negatively charged bacteria. 
Liu and co-workers prepared AgNPs (10 nm of diameter) also coated with a MS shell (50 nm 
of diameter after the coating process) and tested its antimicrobial behavior against V. 
Natriegens.
[242] 
The prepared nanoparticles were able to inhibit V. natriegens growth at 10 g 
mL
-1




organosiloxane polymer that was then deposited in aluminum films.
[243,244]
 The prepared films 
successfully inhibited the formation of bacterial films of V. natriegens. 
Yang, Shen and co-workers proposed a method to fabricate mesoporous silica microcapsules 
with AgNPs loaded onto the interior walls of the MS shell, which gave a sustained-release of 
Ag(I) ions, and displayed high antibacterial durability.
[245] 
AgNPs-MS microcapsules was 
fabricated via a two-step process: (i) Ag(I) ions were adsorbed on the surface of monodisperse 
sulfonated polystyrene beads via electrostatic interaction, and then reduced and protected by 
polyvinylpyrrolidone to obtain sulfonated polystyrene-Ag composite spheres; (ii) then silica 
precursor colloids were assembled on the sulfonated polystyrene-Ag composite spheres via 
hydrogen bond forces to form a silica shell. The prepared composite slowly release Ag(I) ions 
from 6 h to 10 days. The antibacterial activity against E. coli reached up to 99.8% and 
maintained a high level over two months.  
The same authors also prepared an antibacterial film fabricated by loading MS microcapsules 
containing AgNPs on a fluoro-silicone resin film (Figure 11). Moreover, the surface of the 
prepared material was hydrophobically modified by a controlled dosage of fluoro-silicone 
resin solution, to obtain a completely hydrophobic surface and to increase film thickness.
[246] 
A prolonged release of Ag(I) from the prepared composite was achieved over 10 days. The 
films exhibited an excellent antibacterial activity due to (i) the formation of a lotus-leaf-like 
hierarchical micro-nanoscale structured surface, resulting in enhanced hydrophobicity and (ii) 
release of Ag
+
 ions from the mesopore channels.  
Pandey and Ramontja prepared MS microparticles with embedded alginate-coated AgNPs and 
studied its effect in gram positive and gram negative bacteria.
[247] 
In a first step, the authors 
prepared the alginate-coated AgNPs and used this solution to prepare the MS. Using this 
procedure AgNPs were well dispersed onto the MS matrix. Values of MIC for gram positive 
bacteria (S. aureus, S. epidermis, B. cereus, B. subtilis, E. faecalis) ranged from 80 to 250 g 
mL
-1




vulgaris, P. aeruginosa, E. aerogenes) ranged from 55 to 125 g mL
-1
. The authors suggested 
that the microparticles adhered to the bacterial membrane and altered its integrity, thus 
facilitating the bactericidal effect of the AgNPs. 
Yusufu, Cao and co-workers developed a multifunctional bioactive material that stimulated 
osteogenesis and promoted the vascularization of bone marrow stem cells (BMSC) and their 
resistance to bacterial infection.
[248] 
The material consisted of silver nanocrystals coated with a 
MS shell and loaded with the peptide platelet-derived growth factor BB (PDGF-BB) - a 
growth factor that regulates cell growth and division. The aims of the study were to evaluate 
(i) the released of silicon to stimulate osteogenic differentiation of BMSC, (ii) to evaluate the 
BMSC angiostimulation capacity of PDGF-BB, and (iii) the silver ion bactericidal effect of 
the AgNPs on bone modeling and remodeling. After biodegration of the material inside the 
BMSC, Si ions stimulated osteogenic differentiation of BMSC by activating the alkaline 
phosphatase (ALP) activity of bone-related genes and increasing protein (OCN, RUNX2 and 
OPN) expression. Furthermore, the 70±80 % of the loaded PDGF-BB was released during the 
first 10 days and stimulated the angiogenic differentiation of BMSC. Besides, Ag(I)
 
ions were 
released from the interior of the shell, showing suitable release over 14 days. The antibacterial 
activity of Ag(I) from the MS support was evaluated by the OD600 bacterial growth curve 
against E. coli, S. aureus, P. aeruginosa, Bacteroides fragilis, Candida sporogenes over 24 h. 
The results showed high antibacterial activity on E. coli, P. aeruginosa, Bacteroides fragilis 
and Candida sporogenes, however, the prepared material exhibited poor bactericidal effects 
against S. aureus.  
Qiu, Zhang and co-workers proposed a strategy for the preparation of flexible MS fibres 
containing AgNPs as effective wound dressing.
[249] 
Additionally, the mesopores served as 
hosts for the accommodation of ibuprofen (IBU). The loading capacity of IBU reached up to 
18 wt%, and its release was relatively fast; more than 85% of the drug was released within 12 




flexibility, but also allowed slow release of silver overall having a sustained antibiotic effect. 
Besides, antibiotic ability of the fibers with different doping concentrations of AgNPs was 
tested against E. coli. The results showed a sustained antibiotic effect over 48 h. 
Ghosh and co-workers prepared Ag/AgCl-MS NPs against E. Coli.
[250] 
The materials were 
based on SBA-15 containing Ag or AgCl nanoparticles by using two methods: (i) the 
impregnation method (for Ag nanoparticles) and (ii) the ‘one pot’ method (in which SBA-15 
and AgCl nanoparticles were formed at the same time). Antibacterial activity of Ag/AgCl-
MSNs was investigated against E. coli using a conventional plate-count methodology at 24 h. 
All materials showed high antibacterial activity even when the percentage of loaded Ag in the 
nanocomposites was as low as 10 wt%. 
MS NPs loaded with CdTe quantum dots and coated with AgNPs were also used as 
antibacterial materials.
[251] 
The pores of the mesoporous nanoparticles were loaded with 
mercaptopropionic acid-coated CdTe QDs and the external surface functionalized with N-
(aminoethyl)-aminopropyl trimethoxysilane. Finally, Ag(I) ions were coordinated with the N-
(aminoethyl)-aminopropyl moieties and then transformed onto AgNPs using the silver-mirror 
reaction. The prepared nanoparticles were able to kill colonies of E. coli and S. aureus. 
The examples shown above have in common the use of MS containing AgNPs. Moreover, 
there are additional examples in which MS-AgNPs support are additionally loaded with other 
antimicrobials to prepare dual-effect highly efficient bactericidal agents. For instance, 
Santamaría and co-workers developed SBA-15 loaded with peracetic acid and AgNPs.
[252] 
The 
system showed a strong bactericidal effect on antibiotic-resistant biofilms of S. aureus, 
considerably larger than that expected from the summation of the independent effects of both 
antimicrobials. Peracetic acid enhanced the bactericidal effect of Ag(I) by hindering biofilm 
formation and by promoting Ag(I) production by oxidation/dissolution of the AgNPs. The 
protective environment of the mesopores together with a strong peracetic acid adsorption 




Janus silver MS NPs were used by Dong and co-workers to kill E. coli and S. Aureus.
[253] 
The 
Janus nanoparticles consisted of AgNPs linked to a mesoporous phase that contained 
cetyltrimethylammonium bromide (CTAB) inside the pores and aminopropyl moieties grafted 
in the outer surface. PBS suspensions of the prepared Janus nanoparticles were able to release 
CTAB and Ag(I) ions in a sustainable fashion and, as a consequence, killing E. coli (IC50 = 10 
g mL
-1
) and S. Aureus (IC50 = 20 g mL
-1
). The low IC50 obtained was ascribed to a synergic 
effect between the CTAB (which induced a marked loss of bacterial membrane integrity) and 
Ag(I) ions (which are more efficiently internalized). 
Zhou and co-workers prepared MS NPs decorated with AgNPs and loaded with 
chlorhexidine.
[254] 
In a first step the authors prepared, following a co-condensation method, 
MS NPs functionalized with aminopropyl moieties. Then, AgNPs were formed onto the 
mesoporous scaffold by ultrasonication-assisted method using the [Ag(NH3)2]
+
 complex. 
Moreover, the amino groups of the mesoporous scaffold were reacted with succinic anhydride 
and, finally, the pores were loaded with chlorhexidine. The prepared nanoparticles were able 
to release chlorhexidine and Ag(I) ions at acidic pH (5.0) whereas less pronounced delivery 
was observed at neutral pH. Besides, E.coli and S. aureus growth was markedly inhibited in 
the presence of the prepared NPs. MIC of 12.5 and 25 g mL
-1 
for E. coli and S. aureus were 
found. The obtained bactericidal outcome was ascribed to a synergic effect due to the 
simultaneous release of chlorhexidine and Ag(I) ion. 
Chehimi and co-workers functionalized SBA-15 with APTES and polypyrrole was adsorbed 
under ultrasonication. Afterwards AgNPs were prepared inside the pores and the antibacterial 
activity of the systems against E. coli was studied.
[255] 
The material showed a strong 
bacteriostatic effect for concentrations in the 200-300 g mL
-1 
range. The antibacterial 




which ensures the robustness of the nanocomposites, and the antibacterial effect of the 
polypyrrole and AgNPs. 
Guo, Gu and co-workers developed silver core-shell MS NPs loaded with levofloxacin (Ag-
MSNs-Lev) as a synergistic antibacterial agent for the treatment of drug-resistant 
infections.
[256] 
Drug release profile of levofloxacin from Ag-MSNs-Lev or from MSNs-Lev 
was measured at pH 7.4 and a marked and sustainable release of the entrapped drug was 
observed (reaching 95.9 and 83.8% of the loaded levofloxacin for MSNs-Lev and Ag-MSNs-
Lev respectively and after 96 h). Antimicrobial assays were developed by counting the 
number of CFU after cultured the bacteria E. coli and K. pneumoniae 39 in the presence of the 
nanoplatform for 24 h at 37 ºC. Ag-MSNs-Lev exhibited superior antibacterial activity when 
compared to Lev-loaded MSNs and silver embedded MSNs. Ag-MSNs-Lev was evaluated 
also in in vivo acute peritonitis mouse model. Peritoneal cavity of the mice was infected with 
E. coli GN102 and treated with Ag-MSNs-Lev. The results showed a reduction of the 
infection by nearly three orders of magnitude. Moreover, the aberrant pathological of spleen 
and peritoneum disappeared after treatment with Ag-MSNs-Lev. The NPs rendered no 
obvious toxic side effects to mice during the tested time.  
Levofloxacin/silver co-loaded electrospun fibrous membranes were prepared by Cui, Huang 
and co-workers and their in vivo and in vitro antibacterial effect tested.
[257] 
In a first step, the 
authors prepared AgNPs coated with a MS layer and loaded the pores with levofloxacin. Then, 
in a second step, the nanoparticles were incorporated onto electrospun nanofibers of poly-L-
lactide yielding the final nanocoposite (Figure 12). The composite showed an antibacterial 
effect against methicillin-resistant S. aureus (MRSA) at low doses of levofloxacin and Ag 
over 8 weeks (28 mg mL
-1 
levofloxacin and 12 mg mL
-1 
Ag). Besides, in vivo studies in rats 
infected with MRSA were carried out. Treatment with the fibers significantly inhibited S. 





Some examples combine MS with AgNPs and copper derivatives. Lee and co-workers 
prepared Cu(II) impregnated MS nanoparticles loaded with curcumin and containing 
immobilized AgNPs), which showed excellent photodynamic inactivation against E. coli due 
to the synergistic effects of silver, Cu(II) and curcumin.
[258] 
The bactericidal effect of the 
nanoparticles against E. coli in the presence of light (to activate curcumin photosensitizer and 
produce ROS) was higher when compared with the use of curcumin or AgNPs alone. In 
particular, the system resulted in ~90% eradication of the bacterial cells, which accounts to an 
enhancement in bacterial destruction around 5 log and 4 log in comparison to free curcumin 
and Cu-AgNPs, respectively. This observed enhancement is ascribed to the overproduction of 
ROS from AgNPs and curcumin. 
Beyond AgNPs, AuNPs, ZnO, TiO2 and CuO NPs have also been recently used as 
antimicrobial agents. ZnO NPs have been employed in creams, lotions and skin coatings for 
dermatological applications,
[219] 
while TiO2 NPs are currently present in cosmetic products, 
sterile filter, food industries, and for waste water treatment.
[29],[259] 
Particularly, TiO2 
nanoformulation have shown bactericidal activity also towards pathogenic biofilms, 
suggesting their possible use as alternative to antibiotics in the treatment of severe infections 
caused by the generation of mature pathogenic biofilms.
[260–262] 
CuO NPs and AuNPs can 
exert their toxic effect upon pathogenic cells by (i) binding to DNA molecules and, therefore, 
inhibiting their uncoiling and their transcription,
[223] 
or (ii) interacting with amine and 
carboxylic groups (Cu), or S (Au) present in the cellular membranes, which causes the release 
of cell components in the extracellular environment.
[1] 
AuNPs are less efficient than the other 
metal-based NPs.
[263] 
Indeed, these Au-based nanomaterials have enhanced antimicrobial 
properties when photothermally functionalized,
[264] 
when they are bound to antibiotics (e.g., 
ampicillin or vancomycin),
[265,266] 
or when they are added to amino-substituted pyrimidines or 
citrate.
[267] 
Ion release has been indicated as one of the main mechanism of toxicity exerted by 
ZnO NPs, whose Zn
2+






The toxicity of metal oxide NPs, such as CuO or ZnO NPs is also mediated by their 
ability to activate variations in the extracellular environments nearby pathogenic 
microorganisms, therefore leading to the production of ROS along with an increase solubility 
of the NPs themselves.
[269] 
The generation of ROS can also be caused by TiO2 NPs irradiated 
with UV light (usually at λ < 385 nm), causing the photocatalytic production of a strong 
oxidizing power, which in turn results in a cascade of cellular processes,
[270] 
such as lipid 
peroxidation, inhibition of essential enzymes and induction of Nitrogen Reactive Species 
(NRS), and, finally, cell death.
[1],[4],[271,272]
  
Despite these interesting features of AuNPs and nanoparticles of ZnO, TiO2 and CuO, there 
are very few examples of MS incorporating these metal-based antimicrobials. For instance, 
Rosal and co-workers prepared SBA-15 mesoporous particles functionalized by aminopropyl 
moieties and decorated with CuO or with AgNPs. The prepared particles were incorporated 
onto polyethersulfone ultrafiltration membranes.
[273] 
Both types of membranes were able to 
inhibit the growth of E. coli and S. aureus being most effective that containing AgNPs. 
Besides, bacterial adhesion on the prepared membranes was very low. The observed 
antibacterial effect was related with the release of Ag(I) and Cu(II) from the membranes. 
Mosquera and co-workers prepared MS-based nanocomposites, containing CuO as bioactive 
component for application on building stone.
[274] 
The synthetized CuO/SiO2 nanocomposite 
acted as a multifunctional (biocide and consolidant) coating, increased mechanical resistance 
and decreased microbial growth on a typical building limestone. Antibacterial effect of 
CuO/SiO2 nanocomposites on building stone was tested with E. coli and the yeast 
Saccharomyces cerevisiae. The coatings inhibited the growth of bacteria and yeast up to an 
85% and 77%, respectively. The CuO/SiO2 support released Cu
2+
 ions, which played an 
important role in the biocide effect. 
Qu and co-workers prepared bi-functionalized MS-supported AuNPs for antibacterial 
applications.
[275] 




in the internal surface of the pores and with carboxyl groups on the outer surface were 
prepared. Then, reduction of HAuCl4 with NaBH4 in the presence of the bi-functionalized 
silica nanoparticles yielded AuNPs that were fixed onto the mesoporous scaffold. The 
prepared nanoparticles efficiently inhibited the growth of E. coli and S. aureus as a 
consequence of ROS generation induced by AuNPs. Scanning electron microscopy studies 
showed that bacterial surface became rough and wrinkled after the treatment with the NPs. 
The authors ascribed these changes to oxidation of the membrane by the ROS generated by 
the nanoparticles. Besides, the prepared material was also able to destroy B. subtilis biofilms. 
Mijowska and co-workers prepared MS NPs functionalized by TiO2 using the titania 
precursor titanium(IV) butoxide as a photoactive antibacterial agent.
[276]
 The antibacterial 
effects of the TiO2-containing MS on E. coli after 24 h was evaluated by CFU. The assay 
showed strong enhancement upon visible and ultraviolet light irradiation compared with 
commercial TiO2. In darkness, the nanostructure revealed low antibacterial activity. 
Furthermore, the non-cytotoxicity of the TiO2-containing MS was confirmed with WST1 
assay and LDH assay over 24 h on fibroblast cells L929. Mijowska and co-workers also 
prepared MS nanotubes modified with TiO2 as antibacterial agent.
[277] 
The material showed a 
strong enhancement of the antibacterial activity under visible and ultraviolet irradiation on E. 
coli at 24 h. Besides, cell viability using LDH assay over 24 h confirmed the non-toxicity of 
the nanotubes in mouse fibroblast L929 cells. 
A carboxymethyl cellulose hydrogel containing MCM-41 MS NPs decorated with ZnO and 
loaded with tetracycline was prepared by Namazi et al.
[278] 
The MS NPs were introduced into 
an aqueous solution of zinc nitrate, and after filtration, heated at 400ºC for 3 h to generate 
ZnO. Then, the mesoporous NPs decorated with ZnO were loaded with tetracycline and 
incorporated onto a carboxymethyl cellulose hydrogel. Marked inhibition growth of E. coli 
and S. aureus was observed when using the prepared hydrogels mainly due to the tetracycline 




Qian and co-workers developed MS nanospheres functionalized with CdS nanocrystals for 
enhanced photocatalytic and excellent antibacterial activities.
[279] 
The authors prepared 
uniform SiO2/CdS mesoporous nanospheres with an average diameter of 300 nm decorated 
with ca. 5 nm CdS nanocrystals. The antibacterial activity of the mesoporous SiO2/CdS 
nanospheres was evaluated against E. coli. The material was able to kill 70% of the E. coli in 
24 h at concentrations as low as 50 g L
-1
. The mechanism was ascribed to the presence of 
CdS nanoparticles that showed enhanced photon absorption and activated oxygen species 
generation efficiency under visible light irradiation. 
Polarz and co-workers prepared periodic mesoporous silica (PMOs) nanoparticles using 1,5-
bistri(isopropoxysilyl)-benzene-3-sulfonyl chloride and 1,5-bistri(isopropoxysilyl)-benzene-3-
thiol as sol-gel precursors and studied their biocidal activity.
[280]
 The prepared PMOs 
contained thiol and sulfonyl moieties (in different amounts) in the walls of the pores for 
further immobilization of Ag nanoparticles. The prepared PMOs were able to inhibit P. 
aeruginosa growth with MIC in the 0.5-0.25 mg mL
-1
 range due to the sustained release of 
Ag
+
 ions. Besides, confocal laser scanning microscopy studies showed that glass slides coated 
with the prepared PMOs inhibited the growth of P. aeruginosa bacterial films and negligible 
number of alive bacterial were found onto the surface of the films.  
 
3.5. MS loaded with metal ions  
This section highlights examples in which MS are loaded with bactericidal metal cations (MS 
with metal-based NPs are described in the section above). Most of the reported examples are 
loaded with Ag(I), although there are also some examples of MS loaded with copper 
derivatives, Ni(II), Ga(III) and Bi(III). In most cases the metals form complexes with different 
appended ligands and are used as low soluble salts or are adsorbed on MS surfaces. In all 
cases bactericidal activity is a consequence of the delivery of the corresponding metal cation 




account if the antibacterial activity arises simple adsorbed ions or from supported or adsorbed 
metal complexes. 
3.5.1. Containing adsorbed ions 
Calcium-doped MS spheres loaded with Ag(I) ions were prepared ant its antibacterial activity 
tested.
[281] 
The prepared spheres were able to efficiently reduce E. coli (5.5log10 after 2 h) and 
S. aureus (4log10 after 4 h) bacterial population. The antibacterial activity of the spheres was 
ascribed to the sustainable release of Ag(I) ions. Besides, the authors demonstrated that the 
prepared spheres promoted blood clotting, activated the intrinsic pathway of coagulation 
cascade and induced platelet adherence achieving an effective homeostasis in animal models.  
Hong, Yuan, Liu and co-workers also developed amino-functionalized calcium-doped MS 
containing silver ions.
[282] 
A material without amino moieties in which Ag(I) ions were simply 
adsorbed on the MS was also prepared. Antimicrobial tests against E. coli showed that, at the 
same silver ion loading, the Ag(I)-containing amino-functionalized MS displayed longer and 
more efficient (2.5 times lower MIC) antibacterial activity for 24 h compared to the non-
amino-functionalized MS. Further studies demonstrated that the excellent and sustained 
antibacterial efficiency of Ag(I)-containing amino-functionalized MS is attributed to 
complexation of Ag(I) with the amino groups, the strong interaction of the positively-charged 
nanoparticle’s surface with the negatively charged bacteria and the strong inhibition effect of 
Ag(I).  
MS NPs with different aspect ratios (1 (spherical), 2 (small rods) and 4 (larger rods)) were 
prepared using well known procedures by Rosenholm and co-workers.
[283] 
Once the inorganic 
scaffold was prepared the authors adsorbed, through simple electrostatic interactions, Ag(I) 
ions onto the external surface. Finally, the nanoparticles were coated with chitosan 
biopolymer. The antibacterial activity of the prepared nanoparticles was tested against E. coli, 
V. cholerae and S. aureus. The three prepared nanoparticles showed good antibacterial 




the nanoparticles with aspect ratio of 4 which were able to induce a 100% killing of E. coli. 
The MIC of this material for the three bacterial strains was 200 g mL
-1
. SEM images of the 
bacteria treated with the nanoparticles showed a marked elongation with severe membrane 
damage resulting in intracellular protein leakage. Besides, the authors developed a more 
effective treatment against V. cholerae by combining the nanoparticles with aspect ratio 4 
with kanamycin.  
Kwon and co-workers developed an antibacterial material based on silver chloride 
nanoparticles inside the pores of SBA-15.
[284] 
The resulting support was processed with 
polypropylene to form a polymer composite. The antibacterial activity of Ag(I)-containing 
SBA-15 alone and incorporated in the polypropylene polymer was tested against E. coli for 24 
h. Both materials showed a high antibacterial activity. 
In addition to the silver examples, Towler et al reported the use of mesoporous bioactive 
glasses containing different amounts of Ga(III) ion as antimicrobial materials.
[285] 
The authors 
prepared the glasses by using P123 as structure directing agent, tetraethyl orthosilicate, 
triethyl phosphate, calcium nitrate and gallium nitrate (in 1, 2 and 3 mol%). The three Ga(III)-
doped bioactive glasses showed marked antibacterial activity against E. coli and S. aureus. 
The best antibacterial activity was observed for the mesoporous glass containing the higher 
amount of Ga(III). The observed antibacterial effect was ascribed to a sustainable Ga(III) 
release and the efficacy was enhanced with time. Besides, the prepared mesoporous glasses 
displayed a more significant antibacterial activity against S. aureus than against E. coli. This 
different effect was related with the characteristics of the cell walls of the two bacteria. S. 
aureus is surrounded by a peptidoglycan layer with a loosely packed network structure that 
allowed Ga(III) to pass through the wall and reach the interior. On the other hand, E. coli has 
a thicker peptidoglycan wall which difficult Ga(III) internalization. Ga(III) has a similar size 
than Fe(III) and could compete with the later in several biochemical processes with 




Mesoporous silica materials such as KIT-6 (Korea Advanced Institute of Science and 
Technology-6)-encapsulated bismuth oxychloride (BiOCl) were prepared under hydrothermal 
conditions by Chen, Wu, Wei and co-workers.
[286]
 The composite materials xBiOCl/KIT-6 
(molar ratio Bi−Si x = 6, 8, and 10) were labeled as 6Bi−Si, 8Bi−Si, and 10Bi−Si. The 
antibacterial activities of BiOCl−KIT-6 composites were explored against S. aureus and E. 
faecalis, and E. coli and P. aeruginosa over 24 h, showing no activity against gran - bacteria. 
However, the antibacterial effect of BiOCl−KIT-6 composites against S. aureus and E. 
faecalis was pronounced. 6Bi−Si composite had the maximized antibacterial activity against S. 
aureus, and the inhibition rate was up to 96.6% much higher than 10Bi−Si (77.7%), 8Bi−Si 
(91.5%), BiOCl (78.3%), and KIT-6 (52.5%), which is attributed to the mesoporous KIT-6 
support the antibiotic effect of BiOCl. The MICs of 6Bi−Si toward S. aureus and E. faecalis 
were 32 and 40 μg mL
-1
, respectively.  
 
3.5.2. Containing supported or adsorbed metal complexes 
Ghosh and Vandana prepared MS flakes that where functionalized, using a grafting procedure, 
with aminopropyl moieties. Then, the primary amines were reacted with formaldehyde in 
order to decorate the inorganic support with -NH-CH2-OH groups. Finally, Ag(I) was 
complexed with the -NH-CH2-OH moieties yielding the final support.
[287] 
Experiments carried 
out by the authors showed a complete inhibition growth using 70 and 110 g mL
-1
 of the 
particles for E. coli and S. aureus, respectively.  
Other MS NPs which released Ag(I) were also prepared by Lee and co-workers.
[288] 
The 
nanoparticles were first functionalized with butylaldehyde and then, indole-3-acetic acid 
hydrazide was grafted through the formation of imine bonds with the previously anchored 
aldehyde. Finally, Ag(I) was complexed with the indole-3-acetic acid moieties by adding 
silver nitrate to an aqueous suspension of the NPs. The prepared nanoparticles were able to 




bonds, whereas at neutral pH only a moderate delivery was observed (ca. 25% of the ion). The 
NPs completely inhibited the growth of E. coli and S. aureus when using at 120 g mL
-1
 
concentration. Besides, NPs were also able to inhibit the formation of biofilms of E. coli, B. 
subtilis, S. aureus and S. epidermis at doses as low as 30 g mL
-1
. The observed bacterial 
death was ascribed to the Ag(I)-induced ROS generation which resulted in bacterial cell 
membrane damage. Besides, the prepared nanoparticles showed a good antibacterial activity 
in vivo in C57BL/6 mouse with an intraperitoneal E. coli infection. 
Chen and co-workers prepared SBA-15 microparticles functionalized with 
ethylenediaminetretraacetic acid (EDTA) which was able to coordinate high valence silver 
ions.
[289] 
SBA-15 microparticles functionalized with aminopropyl moieties were obtained by 
the co-condensation method and then, the amino groups were functionalized with EDTA 
using thionyl chlroride to activate the carboxylate groups. Finally, addition of silver nitrate 
induced the formation of Ag(II)-EDTA and Ag(III)-EDTA complexes. The prepared 
microparticles were able to inhibit E. coli and S. aureus growth with IC50 values of 30 g mL
-
1
 for both bacteria. Besides, inhibition zone assays indicated that microparticles could be 
stored for 210 days without any remarkable loss in its antibacterial properties.  
Apart of the examples using Ag complexes some authors have also used AgCl as source of 
silver. Song and co-workers prepared thiol-functionalized MS particles loaded with silver 
chloride and dispersed in coatings against Candida albicans and S. mutans on a denture 
base.
[290] 
Molar fractions of thiol in the silica precursors were 10% and 20%. The antibacterial 
activity of the hybrid coatings was evaluated by film contact method measuring the reduction 
rate of the microorganisms. The materials with a 10% thiol molar fraction and loaded with 





Rostamnia, Karimi and co-workers growth silver chloride nanoparticles within the pore 
channels of SBA-15 functionalized with SO3H groups as a system with antibacterial 
properties against E. Coli.
[291] 
The growth of AgCl NPs within the pore channels of the SBA-
15 MS was achieved by sequential dipping steps in alternating baths of KCl and AgNO3 under 
ultrasound irradiation at pH 9. The solid gave a remarkable antibacterial activity against E. 
coli when compared with the same support without Ag(I) ions. 
Compared with silver, less examples using the bactericidal effect of copper cations have been 
reported in MS. Laskowski and co-workers two different SBA-15 materials containing (i) 
copper ions bonded inside the pores via propylphosphonate units (SBA-prop-POO2Cu) 
forming copper-containing groups in concentrations of 10% and 5%, or (ii) free CuO.
[292] 
The 
materials were used to study the antibacterial effect on E. coli. The obtained results showed 
that the sample with a lower concentration of active copper-containing groups had stronger 
antimicrobial properties than the one with the higher concentration at 24 h. The MS 
containing CuO support had no antimicrobial properties. 
Páez, Gómez-Ruiz and co-workers prepared MS NPs containing a maleamato ligand (MS NP-
maleamic) which was used to coordinate copper(II) ions (MS NP-maleamic-Cu) and explored 
their potential application as antibacterial agents against E. coli and S. aureus (see Figure 
13).
[293]
 The results showed a low activity of MS NP-maleamic and MS NP-maleamic-Cu 
against S. aureus, while a good activity against E. coli was found. The material MS NP-
maleamic-Cu (MIC of 4.1 μg mL
-1
) was more active than MS NP-maleamic (MIC of 10.4 μg 
mL
-1
) against E. coli.  
Sedaghat and co-workers prepared MS NPs functionalized with 3-aminopropyltriethoxysilane 
which was reacted with 2-hydroxy-3-methoxybenzaldehyde to obtain a Schiff base.
[294] 
The 
latter material was then treated with Cu(II) and Ni(II) separately to obtain copper and nickel 
complexes anchored on the mesoporous support. The nanocomposites were investigated for 




aeruginosa) bacteria. The results of the growth curve of treated bacteria showed that MS 
nanoparticles having the Ni(II) complex had bactericidal effect against S. aureus while the 
MS NP and MS NP functionalized with the Cu(II) complex displayed only inhibitory effect 
and caused growth retardation of this bacterium. All three solids (i.e. MS NP and those 
containing the Ni or Cu complexes) were bacteriostatic against E. coli and caused reduction of 
bacterial growth. All compounds were found to be good carriers for gentamicin and both, 




We have herein reviewed the use of MS-based materials with bactericidal properties. Due to 
high specific surface area and volume, tunable surface charge/pore size, stability, easy 
functionalization, biocompatibility and the possibility of creating hierarchical structures make 
MS particles excellent candidates for antimicrobial applications. Although, MS have no 
antimicrobial properties by itself, the functionalization and loading with different 
antimicrobials allow preparing a myriad of new hybrid MS materials with enhanced 
bactericidal properties. Antimicrobials based in small-molecules, metal-NPs or metal 
complexes can be adsorbed/functionalized or loaded in MS. In most cases the antibacterial 
efficacy of the prepared materials are significantly higher than that of free antimicrobials. 
Adsorbed/functionalized antimicrobials are usually not delivered and its effectivity is related 
with an effective raising of the local concentration of the antimicrobial due to its anchoring or 
adsorption on the MS surface. Moreover, MS can also serve as suitable containers for 
antimicrobials that are delivered in most cases by simple diffusion from the mesopores to the 
medium. This usually allows a sustained delivery and enhanced bactericidal properties. 
Moreover, MS in the forms of nanoparticles allow to design carriers able to target certain 




few examples have been reported. Both, micro- and nano-MS have also been incorporated in 
composites in advanced antimicrobial applications. An alternative to simple sustained 
delivery is the possibility to design gated MS, in which payload release is triggered by 
predefined stimuli at will. The design of such gated mesoporous materials, capable of 
controlling on-command the release of species in the presence of a predefined stimulus, have 
proved very fruitful in other areas. However, despite the obvious advantage of using this 
approach, gated MS for antimicrobial applications have been not fully explored and new 
advances are envisioned in this area. A further advantage of using MS as nanocontainers is 
the possibility to couple MS with metal-based NPs having well-known antibiotic properties 
such as AgNPs and others. Most interesting MS are excellent supports to load and codeliver 
different antimicrobials at the same time in order to have an enhanced synergistic response. 
Despite the exponential development of this field, drawbacks still need to be overcome. It 
must be recognized that in most published works, studies on the antimicrobial activity is 
reported, yet there are fewer examples designed for real applications. Moreover, 
biocompatibility/biodegradation/toxicity behavior and degradation/clearance of MS in vivo 
and their exploitation as antibiotic delivery are still in its infancy and need to be better 
elucidated and more accurately assessed. Although several system (most of them based in 
metal NPs) have already found application in biomedical and industrial settings, the necessity 
to develop innovative antimicrobial formulations that cause little or no AMR mechanisms 
represents still an urgency for human and animal health, resulting in the unceasing research of 
nanomaterials that can constitute ideal antimicrobial candidates. We expect this review will 
help researchers working in MS and studying bacteria’s resistance to antimicrobial 
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PMO and MONCo-condensation methodGrafting method  
 















































































































































































































































































































































































































































































N-halamine: R1,R2 = H or Cl or Br 
or inorganic group or organic 




Chart 1. Chemical structures of the cargos loaded into the inorganic supports used in the 




















































Figure 2. Silylated natural fatty acids used to functionalize SBA-15 and to prepare PMOs 







Figure 3. MSNs loaded with methylene blue and coated with aminopropyl or with mannose 
moieties with antibacterial photodynamic activity. 
 
 
Figure 4. MSNs loaded with ciprofloxacin and functionalized with arginine for targeting and 






Figure 5. Multifunctional nanoplatform based on MSNs and containing C-dots, Rose Bengal 





Figure 6. MSNs loaded with vancomycin and capped with -poly-L-lysine that were used as 







Figure 7. MSNs derivatized with fluorescein, loaded with vancomycin and capped with a pH-
sensitive hydrogel for the efficient killing of E. coli. 
 
 
Figure 8. MSNs loaded with sulbactam and coated with a metal-organic framework used for 










Figure 10. Schematic representation of the layer-by-layer synthesis of self-assembled 




Figure 11. Fluoro-silicone resin film with MS microcapsules containing AgNPs embedded 






Figure 12. Antibacterial electros pun fibres containing AgNPs coated with a mesoporous 




Figure 13. Schematic representation of the synthesis of MS NPs containing a maleamato 
ligand and the subsequent coordination of copper (II) ions. 
 











































































AgNPs Hollow MSPs 
(HMSPs) 
AgNPs loaded E. coli ND [238] 
AgNPs MSNs mercaptopropyl 
moieties functionalized/ 
AgNPs loaded 



















Ag nanocrystals less 

























MSNs embedded in an 
organosiloxane polymer 
and deposited in 
aluminum films 
V. natriegens ND 
 
[243] 
AgNPs MSNs 10 nm AgNPs/ 50 nm 
MNSs/ silver 
nanoparticles 





MSNs embedded in an 
organosiloxane polymer 
and deposited in 
aluminum films 
AgNPs MSPs silver absorbed into 
sulfonated polystyrene 
beads/ AgNPs loaded 
E. coli ND [245] 
AgNPs MSPs loading MSPs-AgNPs 
on a fluoro-silicone 
resin film/ AgNPs 
loaded 
E. coli ND [246] 
AgNPs MSPs embedded sodium 
alginate-coated AgNPs 
S. aureus,  
S. epidermis,  
B. cereus,  
B. subtilis,  
E. faecalis, 
E. coacae,  
E. coli,  
K. oxytoca,  
K. pneumonia,  
P. mirabilis,  
P. vulgaris,  







AgNPs MSNs silver nanoparticles 
functionalized/ peptide 
platelet-derived growth 
factor BB loaded 
E. coli,  
















AgNPs SBA-15 silver nanoparticles 
functionalized or core 
shell formed 
E. coli ND [250] 



























S. aureus,  
E. coli 
 
















S. aureus,  
E. coli 
 



























MSNs levofloxacin loaded/ 
silver nanoparticles 























SBA-15 aminopropyl moieties 
functionalized/ silver 
nanoparticles or cupper 
ions functionalized 




AgNPs PMOs PMOs contained thiol 
and sulfonyl moieties/ 
inhibit bacterial 
biofilms 





AuNPs MSNs aminopropyl moieties 
























300 nm /antimicrobial 
agent functionalized 





MSNs antimicrobial agent 
loaded/ inhibit bacterial 
biofilms 
S. mutans,  
S. sobrinus,  














Copper ions Silica-based 
nanocomposites 
metal ions contained S. cerevisiae ND [274] 
Copper ions SBA-15 metal ions loaded or 
functionalized 
E. coli ND [292] 
Copper ions MSNs maleamato ligand 
functionalized and 
coordinaed with copper 
(II) ions 













copper and nickel 
complexes anchored/ 






Gallium ions  Mesoporous 
bioactive glasses 
metal ions contained S. aureus,  
E. coli 
ND [285] 













































impregnation (IP) and 
surfactant-assisted drug 
















S. auerus ND 
 
[201] 






E. coli 5 g mL
-1
 [213] 
Linezolid MCM-48 440 nm/ antibiotic 
adsorption loaded 
S. aureus ND [199] 
Lysine MCM-41 antimicrobial agent 
functionalized 
S. aureus, 
E. coli  
ND [148] 
Lysozyme MSNs antimicrobial agent 
functionalized 






































Methylene blue MSNs antimicrobial agent 
functionalized 
E. coli,  
P. aeruginosa 
ND [162] 
Moxifloxacin MSNs functionalized with 
disulfide snap-tops/ β-
CD capped/ redox-
triggered gated MSNs/ 
antimicrobial agent 
loaded 





N-halamine MSNs antimicrobial agent 
functionalized 
S. aureus, 
E. coli  
 
ND [153] 
N-halamine SBA-15 antimicrobial agent 
functionalized 
S. aureus, 






N-halamine SBA-15 antimicrobial agent 
functionalized 
S. aureus, 
E. coli  
 
ND [155] 
N-halamine SBA-15 antimicrobial agent 
functionalized 
S. aureus, 























Parmetol S15 MCM-48 400 nm/ functionalized 






















S. aureus ND [163] 
Rose Bengal/ 
ampicillin 
C-dots MSNs photodynamic 
synergetic therapy/ 
Rose Bengal-MSN@C-










Rose Bengal,  
S-nitrosothiol 
MSNs antimicrobial agent 
functionalized 
P. aeruginosa ND [161] 
rhBMP-2 SBA-15 macroporous scaffolds 








Silver ions Calcium-doped 
mesoporous 
silica spheres 
metal ions loaded S. aureus, 
E. coli 
ND [281] 













rods and larger 
rods MSNs 




S. aureus,  
E. coli, 






Silver ions MSNs  amino-functionalized/ 
silver nanoparticles 
formed 














S. aureus,  








Silver ions SBA-15 aminopropyl and 
ethylenediaminetretraac










Silver ions MSPs thiol-functionalized/ 













Silver ions SBA-15 silver nanoparticles 
functionalized at pH 9 
E. coli ND [291] 
Silylated natural fatty 
acids 
SBA-15 antimicrobial agent 
functionalized 
S. aureus,  
E. coli,  









Tetracycline MSNs antimicrobial agent 
loaded 
E. coli ND [165] 

























and tubes MSNs 
antimicrobial agent 
loaded 










TiO2 MSNs antimicrobial agent 
functionalized 





















Vancomycin/ rifampin SBA-15 antimicrobial agent 
loaded 
S. aureus,  
S. epidermis 
ND [183] 






















MSNs poly (N-isopropyl 
acrylamide-co-acrylic 
acid) copolymerized 










Vinyl carbazole SBA-15 antimicrobial agent 
functionalized 
S. aureus,  
S. mutans,  
E. coli, 







Vinyl imidazole SBA-15 antimicrobial agent 
functionalized 
S. aureus,  
S. mutans,  
E. coli, 






Zinforo MCM-48 100 nm/ matrix-assisted  
pulsed  laser  evapora- 
tion (MAPLE)-
deposited coatings or 
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